Contract
dated as
of July 16, 2008
with
respect to
NEEDLETECH
PRODUCTS, INC.
by and
among
THERAGENICS
CORPORATION
as
Purchaser,
XXXXXX
XXXXXXXX
as
Sellers’ Representative,
THE
INDIVIDUAL STOCKHOLDERS OF NEEDLETECH PRODUCTS, INC.
LISTED ON
SCHEDULE 1 TO
THIS AGREEMENT
as
Sellers,
and
ROCKLAND
TRUST COMPANY,
as
Special Fiduciary and Trustee.
TABLE
OF CONTENTS
This
Table of Contents is not part of the Agreement to which it is attached but is
inserted for convenience only.
Page
|
||
ARTICLE
I DEFINITIONS
|
1
|
|
Section 1.01
|
Definitions
and Construction.
|
1
|
ARTICLE
II SALE AND TRANSFER OF SHARES; CLOSING
|
12
|
|
Section 2.01
|
Purchase
and Sale of Company Shares
|
12
|
Section 2.02
|
Executed
Stock Powers
|
12
|
Section 2.03
|
Purchase
Price and Adjustment of Purchase Price.
|
12
|
Section 2.04
|
Payment
of Purchase Price
|
13
|
Section 2.05
|
Allocation
of Purchase Price Paid to ESOP
|
13
|
Section 2.06
|
Closing.
|
14
|
Section 2.07
|
Closing
Deliverables
|
14
|
Section 2.08
|
Further
Assurances; Post-Closing Cooperation
|
14
|
ARTICLE
III REPRESENTATIONS AND WARRANTIES OF EACH SELLER
|
||
AND
THE COMPANY
|
15
|
|
Section 3.01
|
Organization,
Standing and Power.
|
15
|
Section 3.02
|
Authority
|
15
|
Section 3.03
|
No
Conflicts
|
16
|
Section 3.04
|
No
Consents
|
16
|
Section 3.05
|
Title
to Assets and Properties, Company Shares; Absence of
|
|
Encumbrances
|
17
|
|
Section 3.06
|
Financial
Statements and Schedules.
|
17
|
Section 3.07
|
Ordinary
Course
|
18
|
Section 3.08
|
Absence
of Undisclosed Liabilities.
|
20
|
Section 3.09
|
Litigation;
Regulatory Compliance
|
20
|
Section 3.10
|
Product
Liability Claims
|
21
|
Section 3.11
|
Restrictions
on Business Activities
|
21
|
Section 3.12
|
Governmental
Authorization.
|
21
|
Section 3.13
|
Intellectual
Property
|
21
|
Section 3.14
|
Environmental
Matters
|
25
|
Section 3.15
|
Taxes
|
27
|
Section 3.16
|
Employee
Benefit Plans
|
27
|
Section 3.17
|
Capitalization
and Equity Ownership.
|
31
|
Section 3.18
|
Certain
Agreements Affected by the Acquisition
|
31
|
Section 3.19
|
Employee
Matters.
|
32
|
Section 3.20
|
Interested
Party Transactions
|
34
|
Section 3.21
|
Insurance
|
34
|
Section 3.22
|
Books
and Records.
|
34
|
i
Section 3.23
|
Bank
Accounts
|
35
|
Section 3.24
|
Brokers’
and Finders’ Fees; Third Party Expenses
|
35
|
Section 3.25
|
Customers,
Suppliers and Sales Representatives
|
35
|
Section 3.26
|
Contracts
and Licenses.
|
36
|
Section 3.27
|
No
Breach of Business Contracts or Business Licenses
|
37
|
Section 3.28
|
Third
Party Consents
|
37
|
Section 3.29
|
Solvency
|
37
|
Section 3.30
|
Absence
of Certain Business Practices
|
38
|
Section 3.31
|
Disclosure
of Certain Financial Relationships
|
38
|
Section 3.32
|
Real
Property.
|
38
|
Section 3.33
|
Names.
|
38
|
Section 3.34
|
Competition
|
38
|
Section 3.35
|
Representations
Complete.
|
38
|
ARTICLE
IV REPRESENTATIONS AND WARRANTIES OF THE SPECIAL
|
||
FIDUCIARY
AND TRUSTEE
|
39
|
|
Section 4.01
|
Organization
and Qualification
|
39
|
Section 4.02
|
Authority
|
39
|
Section 4.03
|
No
Conflict
|
39
|
Section 4.04
|
Status
of Special Fiduciary and Trustee
|
40
|
Section 4.05
|
Counsel
to Special Fiduciary and Trustee.
|
40
|
Section 4.06
|
Broker’s
Fee
|
40
|
Section 4.07
|
Claims
Against the Company.
|
40
|
Section 4.08
|
Equity
Ownership.
|
40
|
ARTICLE
V REPRESENTATIONS AND WARRANTIES OF PURCHASER
|
41
|
|
Section 5.01
|
Organization,
Standing and Power.
|
41
|
Section 5.02
|
Authority
|
41
|
Section 5.03
|
No
Conflict
|
41
|
Section 5.04
|
Litigation;
Regulatory Compliance
|
42
|
Section 5.05
|
No
Further Representations.
|
42
|
ARTICLE
VI COVENANTS AND AGREEMENTS
|
42
|
|
Section 6.01
|
Conduct
of Business by the Company Pending the Closing
|
42
|
Section 6.02
|
Notice
of Certain Events
|
44
|
Section 6.03
|
Access
to Information; Confidentiality
|
45
|
Section 6.04
|
No
Solicitation of Transactions.
|
45
|
Section 6.05
|
Financial
Statements and Reports
|
46
|
Section 6.06
|
Delivery
of Books and Records; Removal of Property.
|
46
|
Section 6.07
|
Notice
and Cure.
|
47
|
Section 6.08
|
Fulfillment
of Conditions
|
48
|
Section 6.09
|
Further
Action; Consents; Filings
|
48
|
Section 6.10
|
Public
Announcements.
|
48
|
Section 6.11
|
Assistance
and Cooperation
|
49
|
ii
Section 6.12
|
Employee
Benefit Plans
|
49
|
Section 6.13
|
Sellers’
Representative
|
50
|
Section 6.14
|
Approval
of Schedule 1.
|
50
|
Section 6.15
|
Cooperation
of Purchaser Relating to ESOP.
|
50
|
Section 6.16
|
Reimbursement
of Audit Fees.
|
50
|
Section 6.17
|
Employee
Confidentiality, Invention Assignment, Non-Solicitation
|
|
and
Non-Competition Agreement
|
51
|
|
ARTICLE
VII CONDITIONS TO CLOSING
|
51
|
|
Section 7.01
|
Conditions
to the Obligations of Each Party to Consummate the
|
|
Transaction
|
51
|
|
Section 7.02
|
Additional
Conditions to the Obligations of Each Seller and the
|
|
Special
Fiduciary and Trustee
|
51
|
|
Section 7.03
|
Additional
Conditions to the Obligations of Purchaser.
|
52
|
ARTICLE
VIII TERMINATION, AMENDMENT AND WAIVER
|
56
|
|
Section 8.01
|
Termination
|
56
|
Section 8.02
|
Effect
of Termination
|
57
|
Section 8.03
|
Expenses;
Liquidated Damages.
|
57
|
ARTICLE
IX SURVIVAL, INDEMNIFICATION AND ESCROW
|
57
|
|
Section 9.01
|
Survival
|
57
|
Section 9.02
|
Escrow
Fund.
|
57
|
Section 9.03
|
Indemnification
|
58
|
Section 9.04
|
Procedure
for Indemnification.
|
60
|
Section 9.05
|
Assignment
by Purchaser
|
61
|
ARTICLE
X GENERAL PROVISIONS
|
62
|
|
Section 10.01
|
Notices.
|
62
|
Section 10.02
|
Rights
and Remedies Cumulative
|
63
|
Section 10.03
|
Severability.
|
63
|
Section 10.04
|
Assignment;
Binding Effect; No Third Party Beneficiary
|
63
|
Section 10.05
|
Governing
Law.
|
63
|
Section 10.06
|
Waiver
of Jury Trial
|
64
|
Section 10.07
|
Headings;
Interpretation
|
64
|
Section 10.08
|
Counterparts
|
64
|
Section 10.09
|
Mediation.
|
64
|
Section 10.10
|
Entire
Agreement
|
65
|
iii
EXHIBITS/SCHEDULES
|
|
Schedule
1
|
List
of Sellers
|
Schedule
2
|
Resigning
Directors and Officer
|
Schedule
6.17
|
Employees
signatory to
Form of Employee Confidentiality,
|
Invention
Assignment,
Non-Solicitation and Non-Competition
|
|
Agreement
|
|
Schedule
7.03(h)
|
Employees
entering into Form of Employment Agreement
|
Exhibit
A
|
Escrow
Agreement
|
Exhibit
B
|
Form
of Employee Confidentiality, Invention Assignment, Non-
|
Solicitation
and Non-Competition Agreement
|
|
Exhibit
C-1
|
Xxxxxx
Xxxxxxxx Employment Agreement
|
Exhibit
C-2
|
Xxxxxxx
Xxxxx Employment Agreement
|
Exhibit
C-3
|
Form
of Employment Agreement
|
Exhibit
D-1
|
Xxxxxx
Xxxxxxxx Non-Competition Agreement
|
Exhibit
D-2
|
Xxxxxxx
Xxxxx Non-Competition Agreement
|
Exhibit
D-3
|
Xxxxxxx
Xxxxxxxx Non-Competition Agreement
|
Exhibit
E
|
Form
of Sales Representative Agreement
|
Exhibit
F
|
Form
of Lease Agreement
|
[Schedules
and Exhibits omitted. The Company will furnish a copy of any omitted
Schedule or Exhibit to the Commission upon request.]
|
|
|
|
iv
This
STOCK PURCHASE AGREEMENT is made and entered into as of July 16, 2008, by and
among Theragenics Corporation, a Delaware corporation (“Purchaser”), Xxxxxx
Xxxxxxxx, a resident of the Commonwealth of Massachusetts, as Sellers’
Representative pursuant to Section 6.13 hereof, those individual stockholders of
NeedleTech Products, Inc., a Massachusetts corporation (the “Company”) listed on Schedule 1 hereto and
Rockland Trust Company, a Massachusetts trust company, in its capacity as the
special fiduciary and trustee of the ESOP (the “Special Fiduciary and
Trustee”). Capitalized terms not otherwise defined herein have
the meanings set forth in Article
I.
RECITALS
As of the
date hereof, the Sellers and the Special Fiduciary and Trustee are the
beneficial owners of one hundred percent (100%) of the issued and outstanding
capital stock of the Company.
Pursuant
to this Agreement, Sellers and the Special Fiduciary and Trustee shall sell,
transfer, assign, and deliver to Purchaser, and Purchaser shall purchase and
accept from Sellers and the Special Fiduciary and Trustee, for the consideration
and on the terms set forth in this Agreement, the shares of common stock of the
Company, no par value (the “Company Shares”), set forth
opposite the name of each Seller or the Special Fiduciary and Trustee on Schedule 1 hereto,
which Company Shares represent one hundred percent (100%) of the issued and
outstanding capital stock of the Company.
NOW,
THEREFORE, in consideration of the foregoing and the representations,
warranties, covenants and agreements set forth herein, and other good and
valuable consideration, the receipt and adequacy of which are hereby
acknowledged, and intending to be legally bound hereby, the parties hereto
hereby agree as follows:
ARTICLE
I
DEFINITIONS
Section
1.01 Definitions and
Construction.
(a) Certain Defined
Terms. For purposes of this Agreement, the following terms
shall have the respective meanings set forth below. All other
capitalized terms, when used in this Agreement, shall have the respective
meanings assigned to them where they first appear and are defined in this
Agreement.
“Affiliate”, with respect to
any Person, means any other Person that controls, is controlled by or is under
common control with the first Person.
“Agreement” means this Stock
Purchase Agreement, together with all Schedules and Exhibits attached hereto and
referenced herein.
“Ancillary Agreements” means, collectively,
the Xxxxxx Xxxxxxxx Employment and Non-Competition Agreements, the Xxxxxxx Xxxxx
Employment and Non-Competition Agreements, the Escrow Agreement, the Form of
Employee Confidentiality, Invention Assignment, Non-Solicitation and
Non-Competition Agreement, the Form of Employment Agreement, the Xxxxxxx
Xxxxxxxx Non-Competition Agreement, the Form of Sales Representative Agreement,
the Form of Lease Agreement and all other support agreements and other
agreements to be entered into in connection with the transactions contemplated
by this Agreement.
“Assets and Properties” of any
Person means all assets and properties of every kind, nature, character and
description (whether real, personal or mixed, tangible or intangible, absolute,
accrued, contingent, fixed or otherwise and wherever situated), including the
goodwill related thereto, operated, owned, leased or licensed by such Person,
including, but not limited to, Investment Assets, accounts and notes receivable,
chattel paper, documents, instruments, licenses, Contracts, general intangibles,
real estate, equipment, inventory, goods and Intellectual Property.
“Associate”, with respect to
any Person, means any corporation or other business organization of which such
Person is an officer or partner or is the beneficial owner, directly or
indirectly, of ten percent (10%) or more of any class of equity securities, any
trust or estate in which such Person has a substantial beneficial interest or as
to which such Person serves as a trustee or in a similar capacity, the spouse of
such Person, or any relative of such Person or spouse, who shares the same
primary residence of such Person.
“Benefit Plan” means any
bonus, incentive compensation, deferred compensation, pension, profit sharing,
retirement, savings, stock purchase, stock option, restricted stock, stock
grant, stock ownership, stock appreciation rights, phantom stock, leave of
absence, layoff, vacation, day care, dependent care, legal services, cafeteria,
life insurance, health, accident, disability, worker’s compensation or other
insurance, severance, separation, welfare or other employee benefit plan,
practice, policy, agreement or arrangement of any kind, whether written or oral,
including any “employee benefit plan” within the meaning of Section 3(3) of
ERISA.
“Books and Records” of any
Person means all files, documents, instruments, papers, books and records
relating to the business, operations, condition (financial or other), results of
operations and Assets and Properties of such Person, including financial
statements, Tax Returns and related work papers and letters from accountants,
budgets, pricing guidelines, sales and promotional literature, sales and
purchase correspondence, ledgers, journals, deeds, title policies, personnel and
employment records, Contracts, Licenses, customer and supplier lists, telephone
and facsimile numbers, computer files and programs, operating data and plans,
retrieval programs, and environmental studies and plans.
“Business” means the design,
manufacturing and sale of specialty needles, needle systems and related
hand-held, single use medical devices.
2
“Business Contracts” means all
Contracts (other than the Real Property Leases and the Personal Property Leases)
to which the Company is a party and which are used or held for use by the
Company primarily in, or are necessary for, the conduct of the Business as a
going concern, including purchase orders and Contracts related to customers,
suppliers, sales representatives, distributors, as well as Contracts pertaining
to the marketing, manufacturing and testing of products and services of the
Business.
“Business Day” means any day
on which the principal offices of the SEC in Washington, D.C. are open to accept
filings, or, in the case of determining a date when any payment is due, any day
on which banks are not required or authorized by Law or executive order to close
in the State of Georgia.
“Business Licenses” means all
Licenses (including applications therefor), to the extent transferable, which
are used or held for use by the Company primarily in, or are necessary for, the
conduct of the Business as a going concern.
“CERCLA” has the meaning
ascribed to it in the definition of “Environmental Law” under this Section
1.01(a).
“Certificates” has the meaning
ascribed to it in Section 2.02.
“Claim” has the meaning
ascribed to it in Section 9.04(a).
“Closing” has the meaning
ascribed to it in Section 2.06.
“Closing Date” has the meaning
ascribed to it in Section 2.06.
“Closing Balance Sheet” has
the meaning ascribed to it in Section 2.03(b).
“COBRA” has the meaning
ascribed to it in Section 3.16(j).
“Code” means the Internal
Revenue Code of 1986, as amended, and the rules and regulations promulgated
thereunder.
“Company” means NeedleTech
Products, Inc., a Massachusetts corporation.
“Company Authorizations” has
the meaning ascribed to it in Section 3.12.
“Company Intellectual
Property” means all the Intellectual Property that is used or useful in,
or is necessary for, the conduct of the Business as a going concern (including
the Company’s goodwill therein).
“Company Shares” means the
issued and outstanding common stock of the Company.
“Company Plans” has the
meaning ascribed to it in Section 3.16(b).
“Confidential Information”
has the meaning ascribed to it in Section 3.13(m).
3
“Confidentiality Agreement”
means that certain Confidentiality Agreement dated January 25, 2006 between Purchaser and
the Company.
“Contract” means any
agreement, lease, license, evidence of Indebtedness, mortgage, indenture,
security agreement or other contract or arrangement (whether written or oral)
setting forth a legal obligation or right of a party thereto with respect to the
subject matter thereof (including all amendments, supplements thereto,
restatements thereof and consents, waivers and notices thereunder which affect
the rights and/or obligations of any of the parties thereto).
“CPA Firm” has the meaning
ascribed to it in Section 2.03(b).
“Current Assets” means the
aggregate of the amounts with respect to the line items reflected as current
assets in the Pre-Closing Balance Sheet or Closing Balance Sheet, as applicable,
and prepared in accordance with GAAP.
“Current Liabilities” means
the aggregate of the amounts with respect to the line items reflected as current
liabilities in the Pre-Closing Balance Sheet or the Closing Balance Sheet, as
applicable, and prepared in accordance with GAAP.
“Disclosure Schedule” has the
meaning ascribed to it in the introductory paragraph of Article
III.
“Dispute” has the meaning
ascribed to it in Section 10.09.
“$” or “Dollars” means United States
dollars.
“Employees” means all
employees of the Company or its Affiliates employed in connection with the
Business as of the date of this Agreement.
“Encumbrance” means any
mortgage, pledge, assessment, security interest, lease, lien, adverse claim,
levy, charge, right of first refusal or other encumbrance, right or restriction
of any kind, or any conditional sale Contract, title retention Contract or other
Contract to give any of the foregoing.
“Environmental Claim” means
any action, suit, complaint, notice of violation, demand, penalty, written or
oral notice, request for information or other communication, claim,
investigation, order or proceeding relating to: (i) the actual or
alleged violation of any Environmental Law, including, without limitation, any
alleged failure to possess or comply with any environmental approvals, permits,
licenses, clearances and consents required under any Environmental Law; (ii) any
treatment, storage, recycling, transportation, disposal, handling, placement,
Release or threatened Release, or the presence of any Hazardous Material at any
location, whether or not owned by the Person against whom such liability is
alleged or asserted; or (iii) the actual or alleged exposure of any Person to
any Hazardous Material.
“Environmental Law” means any
Law or rule of common law (including, without limitation, nuisance and trespass
claims) of any Governmental Entity, relating to human health, safety, any
Hazardous Material, natural resources or the environment (including, without
limitation, ground, air, water or noise pollution or contamination, and
underground or above-ground storage tanks), and shall include, without
limitation, the Solid Waste Disposal Act, 42 U.S.C. § 6901 et seq.; the
Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42
U.S.C. §9601 et seq. (“CERCLA”), as amended by the
Superfund Amendments and Reauthorization Act of 1986 (“XXXX”); the Hazardous
Materials Transportation Act, 49 U.S.C. § 1801 et seq.; the Federal Water
Pollution Control Act, 33 U.S.C. § 1251 et seq.; the Clean Air Act, 42 U.S.C. §
7401 et seq.; the Toxic Substances Control Act, 15 U.S.C. § 2601 et seq.; the
Safe Drinking Water Act, 42 U.S.C. § 300f et seq., and their state equivalents
or analogs, and any other state or federal environmental statutes, and all
rules, regulations, orders and decrees now or hereafter promulgated under any of
the foregoing, as any of the foregoing now exist or may be changed or amended or
come into effect in the future.
4
“ERISA” means the Employee
Retirement Income Security Act of 1974, as amended, and the rules and
regulations promulgated thereunder.
“ERISA Affiliate” has the
meaning ascribed to it in Section 3.16(b).
“Escrow Agent” has the meaning
ascribed to it in Section 9.02.
“Escrow Agreement” has the
meaning ascribed to it in Section 2.04(b).
“Escrow Amount” has the
meaning ascribed to it in Section 2.04(b).
“Escrow Fund” has the meaning
ascribed to it in Section 9.02.
“ESOP” means the NeedleTech
Products Employee Stock Ownership Plan and the trust established
thereunder.
“ESOP Loan” has the meaning
ascribed to it in Section 2.05(a).
“Exchange Act” means the
Securities Exchange Act of 1934, as amended, together with the rules and
regulations promulgated thereunder, as in effect from time to time.
“Expenses” means, with respect
to any party hereto, all out-of-pocket expenses (including all fees and expenses
of counsel, accountants, investment bankers, experts and consultants) reasonably
incurred by or on behalf of such party in connection with or related to the
negotiation, authorization, preparation, execution and performance of its
obligations pursuant to this Agreement, the Ancillary Agreements and the
consummation of the transactions contemplated by this Agreement, and all other
matters and proceedings related to this Agreement, the Ancillary Agreements, the
transactions contemplated by this Agreement and thereby and the closing of such
transactions.
“Final Closing Working Capital”
has the meaning ascribed to it in Section 2.03(b).
“Financial Statements” has the
meaning ascribed to it in Section 3.06.
5
“Former Employees” means all
individuals who were at one time employees of the Company or its Affiliates and
were employed in connection with the Business.
“GAAP” means accounting
principles generally accepted in the United States of America.
“Governmental Entity” means
any United States federal, state or local and any foreign governmental,
regulatory or administrative authority, agency, commission, court, tribunal or
arbitral body.
“Hazardous Material” means any
material or substance, whether solid, liquid or gaseous: (i) which is
listed, regulated or defined as a “hazardous substance,” “hazardous waste,”
“hazardous material,” “regulated substance,” “toxic substance,” “contaminant,”
“pollutant” or “solid waste,” or otherwise classified or regulated as hazardous
or toxic, in or pursuant to any Environmental Law, or for which a Person may be
subject to liability under any Environmental Law; (ii) which is or contains
asbestos, lead-based paint, radon, any polychlorinated biphenyl, polybrominated
diphenyl ether, urea formaldehyde foam insulation, explosive or radioactive
material, motor fuel, or petroleum (including, without limitation, petroleum
products, by-products, constituents or other petroleum hydrocarbons), fungi,
bacterial or viral matter which reproduces through the release of spores or the
splitting of cells or other means, (including without limitation, mold, toxic or
mycotoxin spores); or (iii) which causes a contamination or nuisance on, in, at,
under, around or affecting any property or a hazard, or threat of the same, to
public health, human health or the environment.
“Indebtedness” of any Person
means all obligations of such Person (i) for borrowed money, whether or not
evidenced by notes, bonds, debentures or similar instruments; (ii) for the
deferred purchase price of goods or services (other than trade payables or
accruals incurred in the ordinary course of business); (iii) under capital
leases; and (iv) in the nature of guarantees of the obligations described in
clauses (i) through (iii) above of any other Person.
“Indemnified Parties” has the
meaning ascribed to it in Section 9.03(a).
“Indemnitee” has the meaning
ascribed to it in Section 9.04(a).
“Indemnitor” has the meaning
ascribed to it in Section 9.04(a).
“Intangible Personal Property”
means all Intellectual Property of the Company, including the items listed in
Section 3.13(h) of the
Disclosure Schedule, and all Intellectual Property of the Company related
to Product-Specific Machinery and Equipment.
“Intellectual Property” means
any or all of the following, and all rights in, to, under, arising out of, or
associated with any or all of the following: (i) all United States,
foreign and international patents and patent rights (including all patents,
patent applications, and any and all divisions, continuations,
continuations-in-part, reissues, re-examinations and extensions thereof, and all
invention registrations and invention disclosures); (ii) all trademarks and
trademark rights, service marks and service xxxx rights, trade names and trade
name rights, service names and service name rights (including all goodwill,
common law rights and governmental or other registrations or applications for
registration pertaining thereto), designs, trade dress, brand names, business
and product names, Internet domain names, logos and slogans; (iii) all
copyrightable works and copyright rights therein (including all common law
rights and governmental or other registrations or applications for registration
pertaining thereto, and renewal rights therefor); (iv) all sui generis database rights,
ideas, inventions, (whether patentable or not), invention disclosures,
improvements, technology, know-how, show-how, formulas, systems, processes,
designs, methodologies, industrial models, works of authorship, technical
drawings, statistical models, algorithms, modules, computer programs, technical
documentation, business methods, work product, intellectual and industrial
property licenses, proprietary information, and customer lists; (v) all mask
works, mask work registrations and applications therefor; (vi) all industrial
designs and any registrations and applications therefor throughout the world;
(vii) all computer software including all source code, object code, firmware,
development tools, files, records and data, and all media on which any of the
foregoing is recorded; (viii) all shop rights and moral rights, (ix) all trade
secrets, trade secret rights, and other proprietary rights in information,
including contractual or other rights to confidential information of third
parties or to have information treated as confidential by third parties; (x) all
similar, corresponding or equivalent rights to, and to the benefits pertaining
to, any of the foregoing, including (without limitation), the right to
institute, defend and/or prosecute all suits and proceedings and retain all
damage and other awards and to take all actions necessary or proper to collect,
assert, or enforce any interest, claim, right, or title of any kind in and to
any and all of the foregoing, or the Assets and Properties; and (xi) all
documentation related to any of the foregoing; provided, however, that the
term “Intellectual
Property” does not include any of the foregoing to the extent that the
rights thereto are in the public domain and not subject to ownership or
proprietary rights on the part of any party.
6
“Inventory” means all
inventory of goods and supplies used or maintained in connection with the
Business of the Company, including medical supplies and office supplies, whether
as finished product, raw material or work in progress, and whether held at, or
in transit from or to, the locations at which the Business of the Company is
conducted.
“Investment Assets” means all
debentures, notes and other evidences of Indebtedness, stocks, securities
(including rights to purchase and securities convertible into or exchangeable
for other securities), interests in joint ventures and general and limited
partnerships, mortgage loans and other investment or portfolio assets owned of
record or beneficially by the Company (other than trade receivables generated in
the ordinary course of business of the Company).
“IRS” means the United States
Internal Revenue Service.
“Law” means any U.S. federal,
state, or local, and any foreign, statute, law, ordinance, regulation, rule,
code, order, judgment, decree, or other requirement or rule of law, as in effect
from time to time, including the Foreign Corrupt Practices Act.
“Legal Expenses” of
Indemnified Parties means any and all reasonable out-of-pocket fees, costs and
expenses of any kind incurred by such Indemnified Parties and its counsel in
investigating, preparing for, defending against, providing evidence, producing
documents or responding to subpoenas in connection with, or taking other action
with respect to any threatened or asserted claim or investigation of a third
party or Governmental Entity, including expenses of investigation, court costs,
and fees and expenses of attorneys, accountants and experts.
7
“Liability” and “Liabilities” means any
Indebtedness, obligation or other liability of a Person (whether absolute,
accrued, contingent, fixed or otherwise, matured or unmatured, determined or
undetermined, or whether due or to become due).
“License” means any license,
permit, certificate of authority, authorization, approval, registration,
franchise and similar consent granted or issued by any Governmental
Entity.
“Loss” has the meaning
ascribed to it in Section 9.03(a).
“Material Adverse Effect” with
respect to the specified Person means any change, effect, event, occurrence,
state of facts or development that, individually or in the aggregate with all
other such changes, effects, events, occurrences, states of fact and
developments, is, or would reasonably be expected to be, materially adverse to
the business, assets, Liabilities, financial condition, operations, results of
operations or prospects (financial or other) of the specified Person; provided, however, that none of the
following shall be deemed in itself to constitute a Material Adverse
Effect: changes, effects, events, occurrences, states of facts or
developments (A) occurring as a result of general economic conditions in the
United States or generally prevailing conditions in the United States financial
markets, or (B) which, in the case of the Business, are not unique to the
Business, but also affect other Persons who participate or are engaged in
businesses comparable to the Business, to the extent, in each case, that such
changes, events, occurrences, states of fact or developments do not have a
materially disproportionate effect on the Business.
“Notice” has the meaning
ascribed to it in Section 9.04(a).
“Notice of Disagreement” has
the meaning ascribed to it in Section 2.03(b).
“Order” means any writ,
judgment, decree, notice, ruling, opinion, stipulation, determination,
injunction or similar order or award of any arbitrator, mediator or Governmental
Entity (in each such case whether preliminary or final).
“Payment Programs” means any
payment program, including without limitation Medicare, TRICARE, Medicaid,
worker’s compensation, Blue Cross/Blue Shield programs, managed care plans,
health maintenance organizations, preferred provider organizations, health
benefit plans, health insurance plans, employee benefit plans, government
sponsored programs, alternative care plans, and other third party reimbursement
and payment programs.
“Permitted Encumbrance” means
(i) any Encumbrance for Taxes not yet due or delinquent or being contested in
good faith by appropriate proceedings for which adequate reserves have been
established in accordance with GAAP; or (ii) any statutory Encumbrance arising
in the ordinary course of Business by operation of Law with respect to a
Liability that is not yet due and payable and does not materially impair the
value of the property subject to such Encumbrance or the use of such property in
the conduct of the Business.
8
“Person” means an individual,
corporation, partnership, limited partnership, limited liability company,
limited liability partnership, syndicate, person (including a “person” as
defined in Section 13(d)(3) of the Exchange Act), trust, association, entity or
Governmental Entity.
“Personal Property Leases”
means (i) the leases or subleases of Tangible Personal Property described in
Section 3.26(a) of the
Disclosure Schedule as to which the Company is the lessor or sublessor,
and (ii) the leases of Tangible Personal Property described in Section 3.26(a) of the
Disclosure Schedule as to which the Company is the lessee or sublessee,
together with any options to purchase the underlying property.
“Pre-Closing Balance Sheet”
means the unaudited balance sheet of the Company dated as of February 29, 2008
as adjusted for GAAP and by any findings resulting from the audit of the
December 31, 2007 and 2006 financial statements performed by Xxxxx
Xxxxxx.
“Pre-Closing Working Capital”
means the Working Capital derived from the Company’s Pre-Closing Balance
Sheet.
“Product-Specific Machinery and
Equipment” has the meaning ascribed to it in the definition for “Tangible Personal
Property”.
“Purchase Price” has the
meaning ascribed to it in Section 2.03(a).
“Purchaser” means Theragenics
Corporation, a Delaware corporation.
“Rate” has the meaning
ascribed to it in Section 9.03(a).
“Real Property Leases” means (i) the leases
and subleases of real property with respect to the Company’s facilities which
are described in Section 3.26(a) of
Disclosure Schedule as to which the Company is the lessor or sublessor,
and (ii) the leases and subleases of real property described in Section 3.26(a) of the
Disclosure Schedule as to which the Company is the lessee or sublessee,
together with any options to purchase the underlying property and leasehold
improvements thereon, and in each case all other rights, subleases, licenses,
permits and profits appurtenant to or related to such leases and
subleases.
“Release” means any past or
present release, spilling, leaking, pumping, pouring, emitting, emptying,
discharging, depositing, escaping, injecting, leaching, dispersing, seeping,
migrating, filtering, dumping, disposing, injecting or other releasing into the
indoor or outdoor environment (including, without limitation, ambient air,
surface water, groundwater, and surface or subsurface strata) or into or out of
any property, whether intentional or unintentional, including, without
limitation, the movement of Hazardous Material on, in, under, above, about,
through or into the air, soil, surface water, or groundwater.
“Representatives” has the
meaning ascribed to it in Section 6.03(a).
“SEC” means the United States
Securities and Exchange Commission.
9
“Securities Act” means the
Securities Act of 1933, as amended, together with the rules and regulations
promulgated thereunder, as in effect from time to time.
“Sellers” means all of the
holders of Company Shares; provided, however, that for purposes of this
Agreement, “Sellers” shall not include the Special Fiduciary and Trustee or the
ESOP.
“Sellers’ Representative” has
the meaning ascribed to it in Section 6.13.
“Special Fiduciary and
Trustee” has the meaning ascribed to it in the introductory paragraph of
this Agreement.
“Subsidiary” means, with
respect to any Person, any corporation, partnership, limited partnership,
limited liability company, limited liability partnership, joint venture or other
legal entity, a majority of the stock or other equity interests or voting power
of which is owned, directly or indirectly, by such Person (either alone or
through or together with any other subsidiary of such Person). For
the avoidance of doubt, Xxxxxxxx-Xxxx LLC shall not be considered a “Subsidiary”
for purposes of this Agreement.
“Tangible Personal Property”
means all furniture, fixtures, vehicles, machinery, equipment, tools (including
machinery and equipment designed exclusively for products of the Business)
(“Product-Specific Machinery
and Equipment”) computers (including computer hardware and software) and
other tangible personal property and all replacement parts therefor which are
used or held for use by the Company primarily in, or are necessary for, the
conduct of the Business as a going concern, and including any of the foregoing
purchased subject to any Encumbrance in favor of any other Person and including
Product-Specific Machinery and Equipment owned or leased by the Company and
located at locations where products of the Business are manufactured or
tested.
“Tax” means (i) any and all
taxes, fees, levies, duties, tariffs, imposts and other charges of any kind
(together with any and all interest, penalties, additions to tax and additional
amounts imposed with respect thereto) imposed by any Taxing Authority,
including, without limitation, taxes or other charges on or with respect to
income, built-in gains, excessive net passive income, franchises, windfall or
other profits, gross receipts, property, sales, use, capital stock, payroll,
employment, social security, workers’ compensation, unemployment compensation or
net worth, taxes or other charges in the nature of excise, withholding, ad
valorem, stamp, transfer, value-added or gains taxes, license, registration and
documentation fees, and customs’ duties, tariffs and similar charges; (ii) any
liability for the payment of any amounts of the type described in clause (i) as
a result of being a member of an affiliated, combined, consolidated or unitary
group for any taxable period; and (iii) any liability for the payment of amounts
of the type described in clause (i) or clause (ii) as a result of being a
transferee of, or a successor in interest to, any Person or as a result of an
express or implied obligation to indemnify any Person.
“Tax Return” means any return,
statement, report or form (including any estimated tax reports and returns,
withholding tax reports and returns and information reports and returns)
required to be filed with respect to any Tax.
10
“Taxing Authority” means any
Governmental Entity or taxing authority responsible for the assessment,
collection or administration of any Tax.
“Working Capital” means the
difference between Current Assets and Current Liabilities.
(b) Construction.
Unless the context of this Agreement otherwise clearly requires: (i)
words of any gender include each other gender and the neuter; (ii) words using
the singular or plural number also include the plural or singular number,
respectively; (iii) the terms “hereof,” “herein,” “hereby,” “hereto” and derivative or
similar words refer to this entire Agreement as a whole and not to any
particular Article, Section or other subdivision; (iv) the terms “Article” or “Section” or other subdivision
refer to the specified Article, Section or other subdivision of the body of this
Agreement; (v) the words “include,” “includes” and “including” shall be deemed to
be followed by the phrase “without limitation” except when preceded by a
negative predicate; and (vi) when a reference is made in this Agreement to a
Schedule or Exhibit, such reference shall be to a Schedule or Exhibit to this
Agreement unless otherwise indicated. All accounting terms used
herein and not expressly defined herein shall have the meanings given to them
under GAAP. The term “party” or “parties” (but not the term
“third party”) when
used herein refers to Purchaser, on the one hand, and the Sellers, the Special
Fiduciary and Trustee, and the Company, on the other hand. When used
herein, the phrase “to the
knowledge of” any Person, “to the best knowledge of” any
Person, “known to” any
Person or any similar phrase, means, in the case of Purchaser, the actual
knowledge of Xxxxxxxxx Xxxxxx, Xxxxx Xxxxx, and Xxxxx Xxxxxxx, in the case of
the Company, the actual knowledge of Xxxxxx Xxxxxxxx, Xxxxxxx Xxxxx, and Xxxxxxx
Xxxxxxxx, in the case of each Seller, the actual knowledge of such Seller, and
in each case, the knowledge that such Person or Persons would have obtained of
the matter represented after reasonable due and diligent inquiry of those
employees and agents of such Person whom such Person reasonably believes would
have actual knowledge of the matters represented. In this Agreement,
any reference to a party conducting its business or other affairs or taking any
action in the “ordinary course
of business” and “ordinary course of business
consistent with past practice” refers to the business and practice of the
specified business as heretofore conducted to the extent: (a) such
action is consistent with such party’s past practices and is taken in the
ordinary course of such party’s normal day-to-day operations; and (b) such
action is not required to be specifically authorized by such party’s
stockholders or members, as applicable, such party’s board of directors or
managers, as applicable, or any committee thereof and does not require any other
separate or special authorization of any nature from a third party.
11
ARTICLE
II
SALE
AND TRANSFER OF SHARES; CLOSING
Section
2.01 Purchase and Sale of Company
Shares. On the
terms and subject to the conditions set forth in this Agreement, at the Closing,
Purchaser hereby purchases, acquires and accepts from Sellers and the Special
Fiduciary and Trustee, and Sellers and the Special Fiduciary and Trustee hereby
sell, assign, convey and deliver to Purchaser, all of their respective rights,
title and interests in and to the Company Shares, free and clear of any
Encumbrances.
Section
2.02 Executed Stock
Powers. At the
Closing, each Seller and the Special Fiduciary and Trustee shall deliver
executed stock powers, in a form reasonably satisfactory to Purchaser, together
with those original certificates that immediately prior to the Closing
represented the Company Shares held by such Seller and the Special Fiduciary and
Trustee, or a duly executed affidavit of lost certificate and indemnity for any
certificate for Company Shares which has been lost, stolen, seized or destroyed
(the “Certificates”),
to Purchaser.
Section
2.03 Purchase Price and Adjustment of Purchase
Price.
(a) Purchase
Price. The aggregate purchase price for the Company Shares is
Forty-Seven Million Eight Hundred Thousand Dollars ($47,800,000) (the “Purchase Price”) subject to
the adjustment as provided in Section 2.03(b). The Purchase Price is
payable in cash at the Closing in the manner provided in Section
2.04.
(b) Adjustment of Purchase
Price.
(i) As
soon as practicable (but in no event later than ninety (90) days after the
Closing Date), Purchaser shall deliver to the Sellers’ Representative an
unaudited balance sheet for the Company dated as of the Closing Date (the “Closing Balance Sheet”)
which shall include a calculation of Working Capital for the Company as of the
Closing Date. The Closing Balance Sheet shall be prepared in
accordance with GAAP as in effect on the Closing Date. The Closing
Balance Sheet shall become final and binding on the Purchaser and the Sellers
unless either party gives written notice of disagreement (“Notice of Disagreement”)
within thirty (30) days following delivery by Purchaser of the Closing Balance
Sheet. Any such Notice of Disagreement shall specify in reasonable
detail the nature of any disagreement so asserted. If Purchaser or
Sellers are unable to resolve the disagreements with respect to the Closing
Balance Sheet within thirty (30) days following the issuance of the Notice of
Disagreement, they shall refer the remaining differences to a certified public
accounting firm mutually agreeable to the parties (the “CPA Firm”), which acting as
experts and not as arbitrators, shall determine only with respect to the
remaining differences so submitted, whether and to what extent, if any, the
Working Capital as calculated based on the Closing Balance Sheet requires
adjustment. Purchasers and the Sellers’ Representative shall direct
the CPA Firm to use its best efforts to render its determination within thirty
(30) days after the date the CPA Firm is selected. The CPA Firm’s
determination shall be conclusive and binding upon the Purchaser and the
Sellers. The fees and disbursements of the CPA Firm shall be paid by
the party whose position regarding the Closing Balance Sheet is not consistent
with the CPA Firm’s determination; provided, however, that in
the event neither party’s position regarding the Closing Balance Sheet was
consistent with the CPA Firm’s determination such fees and disbursements will be
shared equally by the parties. The Working Capital amount that
becomes final and binding on Purchaser and the Sellers under this Section
2.03(b) shall be referred to herein as the “Final Closing Working
Capital.”
12
(ii) After
the calculation of the Final Closing Working Capital, the Purchase Price shall
be adjusted and payments shall be made as follows, not later than five (5)
Business Days following the determination of the Final Closing Working
Capital:
(A) If
the Final Closing Working Capital is less than the Pre-Closing Working Capital,
then the Escrow Agent shall return and deliver to Purchaser out of the Escrow
Fund a dollar amount of cash equal to the difference in excess of
$250,000.
(B) If
the Final Closing Working Capital exceeds the Pre-Closing Working Capital, then
the Purchaser shall pay to the Escrow Agent in cash the difference in excess of
$250,000.
Section
2.04 Payment of Purchase
Price.
The
Purchase Price which is payable at Closing shall be paid as
follows:
(a) that
amount, if any, of the Purchase Price necessary to be paid to the applicable
lenders and other creditors of the Company or Sellers to satisfy and release in
full any Indebtedness and Encumbrances with respect to the Company, or otherwise
obtain clear title to the Company’s Assets and Properties, shall be paid to such
lenders and other creditors in accordance with the payoff letters or other
documentation provided by such creditors;
(b) Purchaser
shall deliver to the Escrow Agent cash in the amount of Four Million One Hundred
Eleven Thousand Five Hundred Dollars ($4,111,500) (the “Escrow Amount”), in
accordance with Article IX and the
escrow agreement entered into on the Closing Date among Purchaser, Xxxxxx
Xxxxxxxx, Xxxxxxx Xxxxxxxx, Xxxxxxx Xxxxx and the Escrow Agent in substantially
the form of Exhibit A hereto
(the “Escrow
Agreement”). Each of Xxxxxx Xxxxxxxx, Xxxxxxx Xxxxxxxx and
Xxxxxxx Xxxxx’x respective interest in the Escrow Amount is set forth opposite
his name on Schedule
1; and
(c) each
Seller’s allocable portion of the balance of the Purchase Price shall be paid to
such Seller in cash in the amount set forth opposite each Seller’s name on Schedule
1.
The
Purchase Price payable to each Seller shall be transmitted by wire transfer or
other immediately available funds to a bank or other account designated by such
Seller.
Section
2.05 Allocation of Purchase Price
Paid to ESOP.
(a) The
portion of the Purchase Price paid to the ESOP that is attributable to Company
Shares in the ESOP that are subject to an Encumbrance and a loan that qualifies
(or was intended to qualify) as an “exempt loan” within the meaning of Treasury
Regulations Section 54.4975-7(b)(1)(iii) (an “ESOP Loan”) will first be
paid to the holder of such ESOP Loan to repay any outstanding balance of the
ESOP Loan in full. Any remaining portion of the Purchase Price
attributable to such Company Shares will then be used by the ESOP to pay proper
ESOP expenses and any remaining amounts will be allocated to the accounts of
ESOP participants and beneficiaries as earnings pursuant to the terms of the
ESOP.
13
(b) The
portion of the Purchase Price paid to the ESOP that is attributable to Company
Shares in the ESOP that have been released from (or were not subject to) an
Encumbrance under the ESOP Loan will be paid to the Special Fiduciary and
Trustee and will be allocated promptly following the Closing by Newco (as
defined in Section 7.02(w)) to the accounts of such ESOP participants and
beneficiaries in accordance with the terms of the ESOP.
Section
2.06 Closing.
The
closing of the purchase and sale of the Company Shares shall take place as of
5:00 pm Eastern Daylight Savings Time on July 31, 2008 (the “Closing Date”) or such other
date and/or time as the parties hereto agree (the “Closing”). The
Closing shall take place at the Atlanta office of Xxxxxx Xxxxxxxxx LLP,
Fourteenth Floor, 0000 Xxxx Xxxxxxxxx Xxxxxx, XX, Xxxxxxx, Xxxxxxx 00000-0000,
or at such other location upon which the parties may mutually
agree.
Section
2.07 Closing
Deliverables. Sellers,
the Special Fiduciary and Trustee and the Company shall deliver to Purchaser and
Purchaser shall deliver to Sellers, through the Sellers’ Representative, and the
Company fully executed originals of the certificates, contracts, documents and
instruments required by Article
VII.
Section
2.08 Further Assurances;
Post-Closing Cooperation. At any
time or from time to time after the Closing, at Purchaser’s request and sole
cost and without further consideration, Sellers and the Special Fiduciary and
Trustee shall execute and deliver to Purchaser such other instruments of sale,
transfer, conveyance, assignment and confirmation, provide such materials and
information and take such other actions as Purchaser may reasonably deem
necessary or desirable in order more effectively to transfer, convey and assign
to Purchaser, and to confirm Purchaser’s title to, the Company Shares, and, to
the full extent permitted by Law, to put Purchaser in actual possession and
operating control of the Company and to assist Purchaser in exercising all
rights with respect thereto.
14
ARTICLE
III
REPRESENTATIONS
AND WARRANTIES
OF
EACH SELLER AND THE COMPANY
As
inducements for Purchaser to enter into this Agreement and to consummate the
transactions contemplated herein, each Seller (with respect to himself, herself
or itself only, and with respect only to the representations and warranties
contained in Sections 3.02, 3.03, 3.04, 3.05(c), 3.20(c), 3.24, and 3.35), and
the Company represent and warrant to Purchaser that, subject to the exceptions
specifically disclosed in writing in a schedule delivered to Purchaser prior to
(or contemporaneously with) the signing of this Agreement (the “Disclosure Schedule”), the
statements set forth in this Article III are true
and correct. The Disclosure Schedule shall be arranged in sections
and subsections corresponding to the numbered sections and lettered subsections
of this Agreement, and all exceptions shall reference a specific representation
set forth in this Article III and shall
apply only to such numbered section and lettered subsection unless expressly
cross-referenced in another numbered section and lettered
subsection.
Section
3.01 Organization, Standing and
Power.
(a) The
Company is a corporation duly organized, validly existing and in good standing
under the Laws of the state of its incorporation. The Company has the
corporate power and authority to own, use, license, lease and operate its
Business and to carry on its Business as it is now being conducted and as
currently proposed to be conducted and is duly qualified, licensed or admitted
to do business and is in good standing in each jurisdiction in which the
ownership, use, licensing, leasing or operation of its Business, or the conduct
or nature of its Business, makes such qualification, licensing or admission
necessary.
(b) The
Company does not own any wholly or partially-owned Subsidiaries.
Section
3.02 Authority.
Sellers
and the Company have the requisite capacity, power and authority, as
appropriate, to enter into, execute and deliver this Agreement and the Ancillary
Agreements to which it is a party, to consummate the transactions contemplated
by this Agreement and the Ancillary Agreements, and to perform its obligations
hereunder and thereunder. The execution and delivery of this
Agreement and the Ancillary Agreements to which the Sellers, the Company or any
of their Affiliates are each a party, and the consummation of the transactions
contemplated by this Agreement and the Ancillary Agreements, have been duly
authorized by all necessary corporate, stockholder and other action on the part
of the Sellers and the Company. This Agreement has been, and the
Ancillary Agreements to which the Sellers and the Company are a party will be,
duly executed and delivered by such parties. This Agreement
constitutes, and the Ancillary Agreements to which the Sellers and the Company
are a party, when executed and delivered as contemplated by this Agreement, will
constitute, assuming due authorization, execution and delivery by each of the
other parties hereto and thereto, valid and binding obligations of such parties,
enforceable against such parties in accordance with their respective terms,
except as such enforceability may be limited by applicable bankruptcy and
insolvency laws, the rights of creditors generally, and equitable remedies
whether asserted in actions at law or in equity.
15
Section
3.03 No Conflicts.
The
execution and delivery by the Sellers and the Company of this Agreement and the
Ancillary Agreements to which they are parties do not, and the consummation by
the Sellers and the Company of the transactions contemplated by this Agreement
and the Ancillary Agreements do not and will not:
(a) conflict
with, or result in any violation or breach of, or default under (with or without
notice or lapse of time, or both) or give rise to a right of termination,
cancellation or acceleration of any obligation or loss of any benefit under (i)
any provision of the Certificate of Incorporation, Bylaws or other charter or
organizational documents of the Company, as presently in effect, or (ii) any of
the Real Property Leases, Business Contracts, Personal Property Leases, Business
Licenses, or any other Contract, or other instrument, permit, concession,
franchise, or License applicable to the Company, its Business or any of the
Assets and Properties of the Company;
(b) conflict
with or result in a violation or breach of, or default under, any Law or Order
applicable to the Company, its Business or any of the Assets and Properties of
the Company that has had, or would reasonably be expected to have, a Material
Adverse Effect on the Business or any Assets and Properties of the
Company;
(c) except
as listed in Section
3.28 of the Disclosure Schedule, (i) conflict with or result in a
violation or breach of, (ii) constitute a default (or an event that, with or
without notice or lapse of time or both, would constitute a default) under,
(iii) require the Sellers or the Company to obtain any consent, approval or
action of, make any filing with or give any notice to any Person as a result or
under the terms of, (iv) result in or give to any Person any right of
termination, cancellation, acceleration or modification in or with respect to,
(v) result in or give to any Person any additional rights or entitlement to
increased, additional, accelerated or guaranteed payments or performance under,
or (vi) result in the loss of any material benefit under any of the terms,
conditions or provisions of, any Business Contract, Business License, Real
Property Lease, Personal Property Lease or any other Contract to which the
Company or any Seller is a party; or
(d) result
in the creation or imposition of (or the obligation to create or impose) any
Encumbrance upon the Business or any of the Assets and Properties of the
Company.
(e) conflict
with any agreement, document, or Law establishing or controlling the
ESOP.
Section
3.04 No Consents.
No
consent, approval, order or authorization of, or registration, declaration or
filing with, any Governmental Entity is required by or with respect to the
Sellers, the Company, the Business or any of the Assets and Properties of the
Company in connection with the execution and delivery of this Agreement or the
Ancillary Agreements or the consummation of the transactions contemplated hereby
or thereby, except for (i) such consents, authorizations, filings, approvals and
registrations which would not prevent or alter or delay any of the transactions
contemplated by this Agreement or any of the Ancillary Agreements, and (ii) as
set forth on Section
3.04 of the Disclosure Schedule, such consents, approvals, orders,
authorizations, registrations, declarations and filings as may be required under
applicable Food and Drug Administration, Drug Enforcement
Administration, CE Xxxx, ISO Certification, Patent and Trademark Office and
Environmental Law authorities.
16
Section
3.05 Title to Assets and
Properties, Company Shares; Absence of Encumbrances.
(a) The
Company has good and valid title to all of the Assets and Properties of the
Company (excluding any assets that are subject to a lease) free and clear of any
Encumbrances except for Permitted Encumbrances. The Assets and
Properties of the Company are not subject to any preemptive right, right of
first refusal or other right or restriction, are in good operating condition and
repair, reasonable wear and tear excepted, are suitable and adequate for use in
the ordinary course of business, and conform in all material respects to all
applicable Laws. Except as set forth in Section 3.05 of the
Disclosure Schedule, the Assets and Properties currently owned or leased
by the Company are sufficient in order to conduct the Business consistent in all
material respects with the manner in which the Company conducts its Business on
and as of the date of this Agreement.
(b) Except
as set forth in Section 3.05 of the
Disclosure Schedule, all of the Real Property Leases and
Personal Property Leases are valid, binding and enforceable on the Company in
accordance with their terms, and, to the knowledge of the Company, are
enforceable against the other party or parties thereto in accordance with their
terms. The Company is not in default under any such lease applicable
to it and there has not occurred any event that, either alone or with the giving
of notice or lapse of time or both, would constitute a default by the Company
under such lease. To the knowledge of the Company, there is no
current default by any other party to any such lease and no event has occurred
that, either alone or with the giving of notice or lapse of time or both, would
constitute a default by such party under any such lease.
(c) Each
Seller has good and marketable title to his or her Company Shares, free and
clear of all Encumbrances (other than restrictions on transfer under applicable
state and federal securities Laws).
Section
3.06 Financial Statements and
Schedules. As set
forth in Section 3.06
of the Disclosure Schedule, the Company has delivered to Purchaser the
Company’s reviewed balance sheet and income statements as of and for the twelve
(12) month periods ended December 31, 2007, 2006 and 2005, respectively, as well
as the Company’s unaudited balance sheet and income statement as of and for the
five (5) months ended May 31, 2008, respectively (together with any
financial statements delivered pursuant to Section 6.05 hereof referred to
collectively as the “Financial
Statements”). The Financial Statements delivered to Purchaser
with respect to the Company are correct and complete in all material respects
and were prepared on a consistent basis throughout the periods indicated and
with each other. However, the Financial Statements are subject to
adjustments necessary to conform to GAAP and adjustments, if any, that result
from the audits of the December 31, 2007 and 2006 financial
statements. The Financial Statements present fairly and accurately
the financial position and operating results of the Company for the periods
indicated therein, subject to adjustments for GAAP and normal year-end audit
adjustments, which audit adjustments are of a normal and recurring nature and
are not material in amount, and in the case of the balance sheet and income
statement as of and for the five (5) months ended May 31, 2008 and the twelve
(12) month period ended December 31, 2005, the absence of notes. The
Company maintains and, through the Closing Date, will continue to maintain a
system of internal accounting controls that is reasonably and in good faith
believed by the Company to be adequate for their intended purpose.
17
Section
3.07 Ordinary
Course. Since
December 31, 2007, the Company has conducted its Business in the ordinary course
consistent with past practice, and there has not occurred any change, event or
condition (whether or not covered by insurance) that has had, or would
reasonably be expected to have, a Material Adverse Effect on the Company or its
Business. In addition, without limiting the generality of the
foregoing, since December 31, 2007:
(a) The
Company has not entered into any strategic alliance, joint development or joint
marketing Contract relating to or involving the Business;
(b) Except
as set forth in Section 3.07 of the
Disclosure Schedule, there has not been any amendment or other
modification (or agreement to do so) or any violation of the terms of any of the
Business Contracts, Business Licenses, Real Property Leases or Personal Property
Leases;
(c) Except
as set forth in Section 3.07 of the
Disclosure Schedule, the Company has not entered into any transaction
with any Seller, officer, director, partner, member or Employee engaged in the
conduct of the Business;
(d) The
Company has not entered into any Contract pursuant to which any other Person is
granted manufacturing, marketing, distribution, licensing or similar rights of
any type or scope with respect to any product of the Business;
(e) Except
as set forth in Section 3.07 of the
Disclosure Schedule, the Sellers and the Company have not authorized,
declared or paid any distributions or dividends to any Person;
(f) Except
as set forth in Section 3.07 of the
Disclosure Schedule, the Company has not received any request for
indemnification, warranty coverage or similar claims with respect to any product
of the Company;
(g) There
has not been any transfer, waiver or release (by way of a License, assignment or
otherwise) to or Encumbrance by any Person of rights to any Company Intellectual
Property;
(h) The
Company has not made or agreed to make any waiver of rights to, or license,
lease or other disposition of, any of the Assets and Properties of the
Company;
(i) Except
as reflected in the Financial Statements, as adjusted for GAAP, the Company has
not made or agreed or determined to make any write-off, write-down or
revaluation of any of the Assets and Properties of the Company or any change in
any reserves or Liabilities associated therewith;
18
(j) The
Company has not granted any severance or termination pay, and has not paid or
agreed or made any commitment to pay any discretionary or stay bonus, to any
Employee or independent contractor of or consultant to the Company;
(k) Except
as set forth in Section 3.07 of the
Disclosure Schedule, the Company has not made, granted or approved any
(A) grant of options, restricted stock or phantom stock or any change in the
vesting schedule applicable thereto, or (B) increase in salary, rate of
commissions, rate of consulting fees, rate or amount of distribution to equity
holders or other compensation of any current Employee, independent contractor or
consultant engaged in the conduct of the Business, and the Company has not paid
or approved the payment of any other consideration of any nature whatsoever to
any current or former Employee or independent contractor of or consultant to the
Business other than salary, commissions or consulting fees and customary
benefits paid to any current or former Employee or independent contractor of or
consultant to the Business that are consistent with the Company’s established
practices, agreements or arrangements as the same existed as of December 31,
2007;
(l) Except
as set forth in Section 3.07 of the
Disclosure Schedule, the Company has not made or changed any election in
respect of any Tax, adopted or changed any accounting method in respect of any
Tax, entered into any Tax allocation agreement, Tax sharing agreement, Tax
indemnity agreement or closing agreement, settlement or compromise of any claim
or assessment in respect of any Tax, or consented to any extension or waiver of
the limitation period applicable to any claim or assessment in respect of any
Tax;
(m) Except
as set forth in Section 3.07 of the
Disclosure Schedule and as reflected in the Financial Statements, as
adjusted for GAAP, the Company has not made any change in accounting policies,
principles, methods, practices or procedures (including for bad debts,
contingent liabilities or otherwise, respecting capitalization or expense of
research and development expenditures, depreciation or amortization rates or
timing of recognition of revenue and expense) used in connection with the
Business;
(n) To
the knowledge of the Company, the Company has observed all Laws and Orders
applicable to the Business;
(o) Except
as set forth in Section 3.07 of the
Disclosure Schedule, the Company has taken all action required to
procure, maintain, renew, extend or enforce the Company Intellectual Property
used or held for use in the Business, including submission of required documents
or fees during the prosecution of patent, trademark, copyright or other
applications for the Company Intellectual Property rights;
(p) There
has been no physical damage, destruction or other loss (whether or not covered
by insurance) that has had, or would reasonably be expected to have, a Material
Adverse Effect on the Business or any Assets and Properties of the
Company;
(q) No
default by the Company under or violation by the Company of any Contract of the
Company has occurred, and to the knowledge of the Company, no event has occurred
which, with notice or lapse of time or both, would constitute such a default or
violation; and
19
(r) Except
as set forth in Section 3.07 of the
Disclosure Schedule, the Company is not obligated to any Person to
maintain, modify, improve or upgrade any of the Assets and Properties of the
Company.
Section
3.08 Absence of Undisclosed
Liabilities. The
Company has no liabilities or obligations of any nature (whether known or
unknown and whether absolute, accrued, contingent, or otherwise) except for
liabilities or obligations reflected or reserved against in the Financial
Statements, as adjusted for GAAP, and current liabilities incurred in the
ordinary course of business since the respective dates thereof.
Section
3.09 Litigation; Regulatory
Compliance.
(a) Except
as set forth in Section 3.09(a) of the
Disclosure Schedule, there is no private or governmental Action or
Proceeding pending, or, to the knowledge of the Company, threatened by or
against the Company relating to the Assets and Properties of the Company or the
operation of the Business, and no judgment, decree or Order applicable to the
Company or any of the Assets and Properties of the Company, that could
reasonably be expected to prevent, enjoin, alter or delay any of the
transactions contemplated by this Agreement or the Ancillary Agreements or to
have a Material Adverse Effect on the Business.
(b) Except
as set forth in Section 3.09(b) of the
Disclosure Schedule, the Company does not currently participate, nor has
it ever participated in the past, in any Payment Programs.
(c) Neither
the Company, nor any director or officer, nor to the knowledge of the Company,
any Employee or agent thereof, with respect to actions taken on behalf of the
Company, (A) has been assessed a civil monetary penalty under Section 1128A of
the Social Security Act or any regulations promulgated thereunder, (B) has been
excluded from participation in any federal health care program or state health
care program (as such terms are defined by the Social Security Act), (C) has
been convicted of any criminal offense relating to the delivery of any item or
service under a federal health care program relating to the unlawful
manufacture, distribution, dispensing or administration of medical supplies,
products or devices, or (D) has been a party to or subject to any Action or
Proceeding concerning any of the matters described in clauses (A) through (C) of
this Section 3.09(c).
(d) The
Company (A) is in compliance in all material respects with all Laws relating to
the operation of the Business, (B) is in compliance in all material respects
with all Laws relating to the manufacturing, labeling, packaging, relabeling,
repackaging, marketing, advertising, use, or sale of medical supplies, products
and devices, and (C) is not subject to any sanction, Order or other adverse
action by any Governmental Entity for the matters described in clauses (A) and
(B) of this Section 3.09(d). This includes the laws, rules and
regulations implemented, enforced or promulgated by the Food and Drug
Administration, the Federal Trade Commission, the Centers for Medicare and
Medicaid Services, the Office of Inspector General, OSHA or comparable laws,
rules and regulations implemented, enforced or promulgated by any Governmental
Entity where the Company’s medical supplies, products and devices are
manufactured, labeled, packaged, relabeled, repackaged, marketed, advertised,
used or sold. The Company has responded to and implemented all
corrective measures in connection with any investigations conducted by the Food
and Drug Administration. The Company is not and has not been in
violation of any outstanding Order that has had, or would reasonably be expected
to have, a Material Adverse Effect on the Company or its
Business. Except in the ordinary course of the Business, consistent
with past practice, the Company is not required to make, and has no reasonable
expectation that it will be required to make, any material expenditures to
achieve or maintain compliance with any Law.
20
(e) There
is no third-party litigation related to the Company or its Business where the
Company or, to the knowledge of the Company, an Employee of the Company, has
been served a subpoena to testify.
Section
3.10 Product Liability
Claims. There: (a)
have been no product or service warranty claims made by customers of the Company
which were not reimbursed or assumed by the Company’s suppliers; (b) have been
no product recalls by the Company, and to the knowledge of the Company, there is
no reasonable basis for any product recalls; and (c) are no product and/or
service warranties outstanding or currently being offered by the Company to its
customers (other than those of third parties for which the Company has no
obligation or responsibility). Furthermore, the Company and any of
its predecessors in interest have not been subject to any product liability
claim relating to any of the products of the Company or operation of the
Business and no such claim is threatened and no circumstance or condition exists
that would give rise to such a claim.
Section
3.11 Restrictions on Business
Activities. There is
no agreement, judgment, injunction, Order or decree binding upon the Company
which has, or would reasonably be expected to have, the effect of prohibiting or
impairing any current business practice of the Company or the continuing conduct
of the Business as currently conducted by the Company.
Section
3.12 Governmental
Authorization. The
Company has obtained each Governmental Entity consent, license, permit, grant,
and other authorization (a) required in connection with the manner in which the
Company currently operates, manufacturers, labels, packages, relabels,
repackages, markets, or advertises medical supplies and products or holds any
interest in any of the Assets and Properties of the Company or (b) that is
required for the operation of the Business or the holding of any such interest
((a) and (b) herein collectively called the “Company
Authorizations”), and all of the Company Authorizations
are in full force and effect, except where the failure to obtain or have any of
the Company Authorizations would not reasonably be expected to have a Material
Adverse Effect on the Business. Section 3.12 of the
Disclosure Schedule sets forth all Company Authorizations currently in
force and, except as set forth in Section 3.12 of the
Disclosure Schedule, no consent or approval of any Governmental Entity or
other third party is necessary in order to consummate the transactions
contemplated by this Agreement.
Section
3.13 Intellectual
Property.
(a) The
Company owns all rights, title and interest in and to, or is licensed to use or
otherwise possesses a valid and enforceable right to use, all the Company
Intellectual Property. No Action or Proceeding or claim to the
contrary or any challenge by any other Person to the rights, title or interests
of the Company with respect to the foregoing is pending or, to the knowledge of
the Company, threatened. The Company has not entered into any
exclusive agreements related to the Company Intellectual Property.
21
(b)
The Company owns all rights, title and interest in and to all of the Company’s
Intellectual Property, free and clear of any Encumbrances.
(c) Except
as set forth in Section 3.13(c) of the
Disclosure Schedule, the Company Intellectual Property constitutes all
the Intellectual Property used or useful in, or necessary for, the conduct of
the Business as it was conducted in the twelve (12) months preceding the date
hereof, as a going concern, and as it currently is conducted, including the
design, development, distribution, marketing, manufacture, use, import, license,
obtaining regulatory approval for, and sale of the products, technology and
services of the Company (including products, technology, methods or services of
the Company currently under development).
(d) No
Action or Proceeding or claim relating to the Company Intellectual Property,
including (without limitation) any interference, reissue, reexamination,
protest, or opposition proceeding before an administrative agency or office, is
pending or, to the knowledge of the Company, threatened against the Company or
any of its officers, directors, customers, licensees, licensors or
Affiliates.
(e) Except
as set forth in Section 3.13(e) of the
Disclosure Schedule, to the knowledge of the Company, none of the
Company’s Intellectual Property infringes or has been alleged to infringe any
Intellectual Property, proprietary or contractual right of any other Person or
has been challenged or threatened in any way.
(f) Each material
License, and any agreement relating thereto, relating to the Business is in
effect, and the Company has not taken or failed to take any action and, to the
knowledge of the Company, no other event has occurred that could subject any
such license agreement to termination or otherwise cause any such license
agreement not to be in effect in the foreseeable future. The Company
has the right to use the Intellectual Property not owned by it without payment
or obligation to a third party, in perpetuity, and, in those instances where a
payment is required, the Company has paid all royalties due and performed all
obligations under all such license agreements. The Company is not
presently in default and has received no notice of default under any such
license agreement.
(g) The
Company has received no request for indemnification or contribution, or to
defend or hold harmless, from any third party in respect of any claim that
relates to the Business.
(h) Section 3.13(h) of the Disclosure
Schedule lists (i) all patents and patent applications and all registered
and unregistered trademarks, trade names and service marks, registered
copyrights, registered domain names, and registered mask works, contained in the
Company Intellectual Property, the jurisdictions in which each such Company
Intellectual Property right has been issued or registered or in which any
application for such issuance and registration has been filed, and the nature
and extent of the ownership interest or other right held in each such Company
Intellectual Property right; (ii) all Licenses, sublicenses and other agreements
as to which the Company is a party and pursuant to which any Person is
authorized to use any Company Intellectual Property; (iii) all Licenses,
sublicenses and other agreements with respect to Intellectual Property of a
third party which are incorporated in, are, or form a part of any product of the
Business; (iv) a description of all Assets and Properties that the Company
considers trade secrets; (v) Intellectual Property not covered by any of the
foregoing; and (vi) the unpatented ideas, improvements and trade secrets of the
Company. Each such item of Company Intellectual Property listed (or
required to be listed) in Section 3.13(h) of the
Disclosure Schedule is owned exclusively by the Company (excluding
Intellectual Property licensed to the Company under any License) and is free and
clear of any Encumbrances. The Company (i) owns exclusively all
trademarks, service marks, trade dress and trade names constituting Company
Intellectual Property, and (ii) owns exclusively, and has good title to, each
copyrightable work that is a product of the Company and each other work of
authorship related to the Business.
22
(i) To
the knowledge of the Company, there is no unauthorized use, disclosure,
infringement or misappropriation of any Company Intellectual Property, or any
third-party Intellectual Property, by the Company or any third party, including
(without limitation) any Employee or former Employee, consultant, or contractor
of the Company. The Company has not entered into any agreement to
defend, indemnify or hold harmless any other Person against any charge or claim
of infringement or misappropriation of any Company Intellectual Property or
third party Intellectual Property.
(j) Except
as set forth in Section 3.13(j) of the
Disclosure Schedule, all patents, registered trademarks, service marks,
copyrights, URLs and domain names owned by the Company are valid and subsisting,
and all necessary registration, maintenance, renewal fees, annuity fees and
taxes in connection with such Company Intellectual Property have been
paid. All necessary documents, affidavits and certificates in
connection with such Company Intellectual Property have been filed with all
relevant patent, copyright, trademark or other authorities in all applicable
jurisdictions, for the purpose of maintaining such Company Intellectual
Property. The Company (i) has not received notice that the Company
has been named as a party in any opposition or in any Action or Proceeding which
involves a claim of infringement of any Company Intellectual Property, or
violation of any trade secret or other proprietary right, of any third party;
(ii) has no knowledge that the manufacturing, marketing, licensing, sale or
offer of licensing or sale of products of the Company infringes or
misappropriates any patent, trademark, service xxxx, copyright, trade secret,
mask work or other proprietary right of any third party; and (iii) has not
brought any Action or Proceeding for infringement of any of the Company
Intellectual Property or breach of any license or agreement involving any of the
Company Intellectual Property against any third party.
(k) To
the knowledge of the Company, the Company has not and does not, in connection
with the operation of the Business (i) own any product, technology, service or
publication, (ii) publish or distribute any material or (iii) engage in any
conduct or speech (oral or written) that would constitute a defamatory or
libelous statement or material that is false advertising or otherwise violate in
any material respect any Law.
(l) The
Company has either (i) obtained ownership of, and is the exclusive owner of, all
Company Intellectual Property by operation of Law or by valid assignment or (ii)
obtained a valid and enforceable license under or to such Company Intellectual
Property that the Company does not already own by operation of Law.
23
(m) The
Company has taken all commercially reasonable steps to protect and preserve the
confidentiality and trade secret status of all information used in the Business
which derives any value from being not generally known or readily ascertainable
by others through legitimate means and is not otherwise protected by issued
patents, trademarks or copyrights of the Company (“Confidential Information”),
and have not permitted the Company’s rights in such Confidential Information to
lapse or enter the public domain. All use, disclosure or
appropriation by a third party of Confidential Information owned by the Company
or, to the Company’s knowledge, has been pursuant to the terms of a written
agreement between the Company and such third party protecting the
confidentiality of and limiting the use of Confidential
Information. All use, disclosure or appropriation by the Company of
confidential and proprietary information known by the Company to be owned by
third parties has been pursuant to the terms of a written agreement permitting
such use, disclosure or appropriation between the Company, as the case may be,
and the owner of such confidential and proprietary information, or is otherwise
lawful. There are no actions that must be taken by the Company within one
hundred and eighty (180) days following the date of this Agreement that, if not
taken, would result in the loss of any Company Intellectual Property, including
the payment of any registration, maintenance or renewal fees, annuity fees and
Taxes or the filing of any responses, documents, applications, affidavits or
certificates for the purposes of obtaining, maintaining, perfecting or
preserving or renewing any such Company Intellectual Property. In
each case in which the Company has acquired from any Person ownership of any
Company Intellectual Property, the Company has obtained a valid and enforceable
assignment sufficient to transfer all right, title and interest in, to and under
such Company Intellectual Property (including the right to seek past and future
damages with respect to such Company Intellectual Property) to the Company and,
to the extent provided for by and reasonably required to protect the Company’s
ownership rights in and to such Company Intellectual Property in accordance with
applicable Laws, the Company has recorded each such assignment of Company
Intellectual Property with the relevant Governmental Entity, including the U.S.
Patent and Trademark Office, the U.S. Copyright Office, or comparable
authorities in any relevant foreign jurisdiction, as the case may
be.
(n) Neither
the execution and delivery of this Agreement and the Ancillary Agreements nor
the consummation of the transactions contemplated hereby and thereby will result
in the Company granting any rights or licenses with respect to the Company
Intellectual Property to any Person.
(o) The
Company has not waived or released any rights, either actively or otherwise,
that have had, or would reasonably be expected to have, a Material Adverse
Effect relating to the Company Intellectual Property.
(p) The
Company has not sent notices to third parties of potential infringement of the
Company Intellectual Property.
(q) All
patents and patent applications relating to products of the Company have
properly identified all inventors, inventorship being determined according to
conventional law regarding inventorship qualifications.
24
(r) The
Company has reviewed all issued patents and pending applications with its patent
counsel and all inventors on such patents and pending applications are properly
named, and any individuals who should not have been named have been removed by
filing appropriate petitions with the U.S. Patent and Trademark
Office.
Section
3.14 Environmental
Matters. Except as
disclosed in Section
3.14 of the Disclosure Schedule:
(a) Neither
the Company nor, to the knowledge of the Company, any Person: (i) has
used, generated, stored, treated, disposed, handled or placed any Hazardous
Material on, in, at, under, around or affecting any property currently or
formerly owned, operated, occupied or leased by the Company (including, without
limitation, property owned or leased pursuant to the Real Property Leases); (ii)
has transported or arranged for the transportation of any Hazardous Material
currently or formerly on, in, at, under, around or affecting any property
currently or formerly owned, operated, occupied, or leased by the Company
(including, without limitation, property owned or leased pursuant to the Real
Property Leases) to any location which is or may become the subject of any
action, suit or proceeding relating to Hazardous Material or any Environmental
Law; or (iii) has disposed of, transported, sold, distributed, or manufactured
any product, substance or material of the Company which is or contains any
Hazardous Material;
(b) There
has been no Release or threatened Release of Hazardous Material by the Company
on, in, at, under, around or affecting any property currently or formerly owned,
operated, occupied or leased by the Company (including, without limitation,
property owned or leased pursuant to the Real Property Leases), or, to the
knowledge of the Company on adjacent parcels of real estate;
(c) There
are no actual, or to the knowledge of the Company, potential conditions or
circumstances, including, without limitation, actual or potential conditions or
circumstances relating to Hazardous Material or Environmental Laws, on, in, at,
under, around or affecting any property currently or formerly owned, operated,
occupied or leased by the Company (including, without limitation, property owned
or leased pursuant to the Real Property Leases), which pose an unreasonable risk
or threat to the environment, the health or safety of persons, or the market
value of such properties;
(d) there
are: (i) no above ground or underground storage tanks, whether in
use, active, closed or abandoned, that are on, in, at, under, around or
affecting any property currently or formerly owned, operated, occupied or leased
by the Company (including, without limitation, property owned or leased pursuant
to the Real Property Leases), and the Company has provided a detailed
description of all above ground or underground storage tanks removed by or on
behalf of the Company, in Section 3.14 of the
Disclosure Schedule; and (ii) no Hazardous Materials which are present
on, in, at, under, around or affecting any property currently or formerly owned,
operated, occupied or leased by the Company (including, without limitation,
property owned or leased pursuant to the Real Property Leases) except those
Hazardous Materials held in compliance with all applicable Environmental Laws
and the presence of which would not trigger any reporting, clean-up or remedial
obligation pursuant to any Environmental Laws;
25
(e) The
Company and all properties currently or formerly owned, operated, occupied or
leased by the Company (including, without limitation, property owned or leased
pursuant to the Real Property Leases) are and have been in compliance with all
Environmental Laws;
(f) The
Company currently holds any and all environmental approvals, permits, licenses,
clearances and consents necessary for the conduct of the Business as such
activities and business are currently being conducted;
(g) There
are no Environmental Claims pending against the Company or, to the knowledge of
the Company and the Sellers, threatened against the Company, by any Person
(including, without limitation, any Governmental Entity), relating
to: (i) the Business, (ii) any of the Assets and Properties of the
Company, (iii) any property currently or formerly owned, operated, occupied or
leased by the Company (including, without limitation, property owned or leased
pursuant to the Real Property Leases), or (iv) any current or former product of
the Company that has been manufactured, sold, distributed, transported or
disposed of. The Sellers have no knowledge of any fact or
circumstance which is reasonably likely to involve the Company in any
Environmental Claims or to impose upon the Company any Liability arising from or
related to any Environmental Law;
(h) There
are no Encumbrances threatened or attached to any real estate property
constituting Assets and Properties of the Company, which arise under or pursuant
to any applicable Environmental Law, and no action of any Governmental Entity
has been taken or, to the knowledge of the Company and the Sellers, is
threatened, which could subject any such real estate property to such
Encumbrances;
(i) The
Company and the Sellers have not entered into any agreement to provide
indemnification to any Person in a manner relating to Hazardous Material or any
Environmental Laws, except for indemnity agreements in favor of lenders or
ground lessors entered into in connection with any loan or credit agreements or
ground leases, for property currently or formerly owned, operated, occupied or
leased by the Company (including, without limitation, property owned or leased
pursuant to the Real Property Leases);
(j) The
Company and the Sellers have provided to Purchaser prior to the execution of
this Agreement, true and complete copies and results of any reports, studies,
analyses, tests, investigation, monitoring or similar documentation within the
knowledge, possession or control of the Sellers and the Company, which pertain
to the presence or potential presence of Hazardous Materials on, in, at, under,
around or affecting any property currently or formerly owned, operated, occupied
or leased by the Company (including, without limitation, property owned or
leased pursuant to the Real Property Leases); and
(k) The
Company is not subject to any material capital expenditures or material
obligations (contractual or otherwise) arising under or relating to
Environmental Laws.
26
Section
3.15 Taxes.
(a) Except
as set forth on Section 3.15(a) of the
Disclosure Schedule, the Company has properly completed and timely filed
all Tax Returns required to be filed by it and has paid all Taxes with respect
to the Assets and Properties and the Business which are due through the date of
this Agreement and will properly complete and timely file all Tax Returns and
pay all Taxes with respect to the Assets and Properties and the Business for
periods through the Closing Date. Except for Permitted Encumbrances,
there is and at Closing there will be (i) no claim for any Tax that is an
Encumbrance against any of the Assets and Properties of the Company or that is
being asserted against the Company with respect to any of the Assets and
Properties or the Business, (ii) no audit of any Tax Return relating to the
Company or any of the Assets and Properties or the Business being conducted by
any Taxing Authority, and (iii) no extension of any statute of limitations on
the assessment of any Tax with respect to the Company or any of the Assets and
Properties or the Business.
(b) The
Company has withheld all amounts required to be withheld by Law from payments
made to any Person, whether that Person is regarded as an Employee, independent
contractor, or otherwise, in the conduct of the Business. The Company
has timely paid to the appropriate Taxing Authority all amounts so withheld or
otherwise due in connection with all such payments, and has timely filed all
requisite returns with the Taxing Authorities with respect to such
Taxes. The Company is not a party to any Tax proceeding with respect
to the withholding of Taxes from any payments made in the conduct of the
Business. To the knowledge of the Company, no investigation is being
conducted against the Company by any Taxing Authority with respect to any of the
above withholding, payment, filing or any other obligations in connection with
the above.
Section
3.16 Employee Benefit
Plans.
(a) Section 3.16(a) of the
Disclosure Schedule lists all Employees employed by the Company and its
ERISA Affiliates as of the date of this Agreement and, with respect to each such
listed Employee, his/her employer, position, salary or hourly rate of pay, and
accrued vacation to be paid for the 2008 calendar year and the amount of accrued
vacation carried over from 2007. No salary or vacation benefits have
been granted to any such Persons on terms and conditions which are more
favorable than those indicated in Section 3.16(a) of the
Disclosure Schedule. Section 3.16(a) of the
Disclosure Schedule lists (to the extent not elsewhere on Section 3.16(a) of the
Disclosure Schedule) all benefits, incentives and any other amounts owed
to each of the Company salaried Employees.
(b) Section 3.16(b) of the
Disclosure Schedule contains a true and complete list of each (i) Benefit
Plan, and (ii) any material employment, indemnification (other than by corporate
charter or bylaws), consulting or severance agreement, under which any Employee
or former Employee has any present or future right to benefits or under which
the Company or any ERISA Affiliate has any present or future liability
(collectively, the “Company
Plans”). Neither the Company nor any entity that is a member
of a controlled group with, under common control with, or otherwise required to
be aggregated with, the Company pursuant to Sections 414(b), (c), (m) or (o) of
the Code (an “ERISA
Affiliate”) has communicated to present Employees or Former Employees of
the Company, or formally adopted or authorized for present Employees or Former
Employees of the Company, any plan not disclosed pursuant to this Section
3.16(b) or any change in any existing Company Plan that is not reflected in the
Company Plan documents made available as described in Section 3.16(c) as to
which the Company or an ERISA Affiliate has any unsatisfied
liability.
27
(c) The
Company has made available to Purchaser a complete and current copy of each
Company Plan document and each amendment thereto and a written description of
each unwritten plan; any trust agreement or insurance contract related to a
Company Plan; the most recent employee handbooks, policies and statements of
practices and, for each such plan subject to ERISA, the most recent summary plan
description, the most recent IRS determination letter for each Company Plan
intended to be tax-qualified under Code Section 401(a); and (i) the three most
recent Forms 5500 and attached schedules, (ii) the three most recent audited
financial statements for each of the Company Plans that is required to have
audited financial statements pursuant to ERISA; and (iii) all applicable
nondiscrimination tests for each of the Company Plans intended to be
tax-qualified under Code Section 401(a) which have been performed for the three
most recent plan years. All average deferral percentage and average contribution
tests for each of the Company Plans intended to satisfy the requirements of Code
Sections 401(k) or 401(m) have been performed and passed for the three most
recent plans years ending before January 1, 2008. Each of the Company
Plans intended to satisfy the requirements of Code Sections 401(a) have passed
all other applicable nondiscrimination tests for the three most recent plan
years ending before January 1, 2008.
(d) The
ESOP Loan has been paid in full, evidence of which is attached to Section 3.16(d) of the
Disclosure Schedule.
(e) The
Company and the ERISA Affiliates have no liability with respect to the Company
Plans and no Encumbrance has arisen under ERISA or the Code on the Assets and
Properties of the Company or the ERISA Affiliates or with respect to the
Business, and no condition or event has occurred or exists with respect to the
Company Plans which would result in an Encumbrance on the Assets and Properties
of the Company or the ERISA Affiliates. No Company Plan is currently
under examination by, or has received notice of a pending or threatened
examination by, the IRS, the United States Department of Labor, the Center for
Medicare and Medicaid Services, or the Pension Benefit Guaranty Corporation
(“PBGC”).
(f) Except
as to those plans identified on Section 3.16(f) of the
Disclosure Schedule as tax-qualified Company Plans (the “Company Qualified Plans”),
neither the Company nor its ERISA Affiliates maintain a Benefit Plan intended to
meet the requirements of Code Section 401(a) and they have no liability with
respect to any Benefit Plan which was previously maintained and was intended to
meet the requirements of Code Section 401(a). The IRS has issued
favorable determination letters (National Office favorable opinion letters in
the case of prototype plans) to the effect that each Company Qualified Plan
qualifies under Code Section 401(a) and that any related trust is exempt from
taxation under Code Section 501(a), and such determination letters remain in
effect and have not been revoked. Copies of all outstanding
applications for a determination letter with respect to each Company Qualified
Plan have been delivered to Purchaser. Except as disclosed on Section 3.16(f) of the
Disclosure Schedule, no Company Qualified Plan has been amended by later
amendments than reflected in each respective determination letter (or National
Office favorable opinion letter in the case of a prototype plan), the remedial
amendment period (within the meaning of Code Section 401(b)) within which an
application for a determination letter can be submitted to the IRS with respect
to such later amendments has not yet expired, and no such later amendments
adversely affect the Company Qualified Plan tax qualification. The
Company Qualified Plans currently comply in form in all material respects with
the requirements under Code Section 401(a), other than changes required by
statutes, regulations and rulings for which amendments are not yet required. No
issue concerning the qualification of the Company Qualified Plans is pending
before or is threatened by the IRS. The Company Qualified Plans have
been administered in all material respects according to their terms (except for
those terms which are inconsistent with the changes required by statutes,
regulations, and rulings for which changes are not yet required to be made, in
which case the Company Qualified Plans have been administered in all material
respects in accordance with the provisions of those statutes, regulations and
rulings) and in accordance with the requirements of Code Section
401(a). Neither the Company, the ERISA Affiliates nor any fiduciary
of any Company Qualified Plan have done anything that would adversely affect the
tax-qualified status of the Company Qualified Plans or the related
trusts.
28
(g) Within
the last five years no termination of any Company Qualified Plan has occurred
nor has a notice of intent to terminate any Company Qualified Plan been issued
by the Company or any ERISA Affiliate and no partial termination of any Company
Qualified Plan has occurred for which full vesting was not
provided.
(h) None
of the Company Plans is subject to Section 412 of the Code or Title IV of ERISA,
and neither the Company nor any ERISA Affiliate has ever maintained a plan
subject to Section 412 of the Code or Title IV of ERISA.
(i) None
of the Company Plans is a “multiemployer plan” within the meaning of Section
3(37)(A) of ERISA, and neither the Company nor its ERISA Affiliates have ever
had an obligation to contribute to a multiemployer plan.
(j) The
Company and the ERISA Affiliates are in compliance with the requirements
prescribed by any and all statutes, orders, governmental rules and regulations
applicable to the Company Plans, including, without limitation, Sections 601
through 734 of ERISA and Sections 104 through 106, 125, 129, 4980B, 4980G, or
9801 through 9812 of the Code and all reports and disclosures relating to the
Company Plans required to be filed with or furnished to any governmental entity,
participants or beneficiaries prior to the Closing Date have been or will be
filed or furnished in a timely manner and in accordance with applicable
law. Section 3.16(j) of the
Disclosure Schedule also lists all of the Former Employees and their
beneficiaries who have elected continuation of health insurance coverage under
the continuation of coverage provisions described in Code Section 4980B and
Sections 601 through 608 of ERISA (“COBRA”) and any similar continuation of
health coverage provisions under applicable state law (“State COBRA”) as
provided by the Company or its ERISA Affiliates’ group health plans and are so
covered.
(k) Neither
the Company nor any ERISA Affiliate has ever participated in a “multiple
employer welfare arrangement” within the meaning of ERISA Section
3(40). Neither the Company nor any ERISA Affiliate sponsors,
maintains, or contributes to a trust that is part of a Company Plan, which trust
is intended to be exempt from federal income taxation pursuant to Code Section
501(c)(9). Furthermore, each Company Plan which is an “employee
welfare benefit plan” within the meaning of Section 3(1) of ERISA may be
unilaterally amended or terminated in its entirety without liability except as
to benefit accrued thereunder prior to such amendment or
termination.
29
(l) The
Company and the ERISA Affiliates have made full and timely payment of, or have
accrued, pending full and timely payment, all amounts which are required under
the terms of each of the Company Plans and in accordance with applicable laws to
be paid as a contribution to each of the Company Plans and no excise taxes are
assessable as a result of any nondeductible or other contributions made or not
made to a Company Benefit Plan. The assets of all Company Plans which are
required under applicable laws to be held in trust are in fact held in trust,
and the value of the assets of each such Company Benefit Plan equal or exceed
the liabilities of each such plan.
(m) The
Company, the ERISA Affiliates and each other “disqualified person” and any
“party in interest” (as defined in Code Section 4975 and ERISA Section 3(14),
respectively) with respect to the Company Plans, have not engaged in any
“prohibited transaction” (as defined in Code Section 4975 or ERISA Section 406)
or a breach of ERISA Section 404.
(n) Neither
the Company nor the ERISA Affiliates have made or are obligated to make any
nondeductible contributions to any of the Company Plan for the current or future
tax years.
(o) Other
than routine claims for benefits, there are no actions, audits, investigations,
suits or claims pending, or, to the knowledge of the Company, threatened against
any of the Company Plans, any trust or other funding agency created thereunder,
any fiduciary of any of the Company Plans, the assets of any of the Company
Plans, or the Company or an ERISA Affiliate with respect to the Company
Plans.
(p) Except
for Company Qualified Plans and except as listed in Section 3.16(p) of the
Disclosure Schedule, neither the Company nor the ERISA Affiliates have
any obligation to any Former Employee or any Employee upon retirement or
termination of employment under any of the Company Plans. Neither the
Company nor the ERISA Affiliates maintain, or are obligated to make
contributions to or under any plan which provides post-retirement or
post-termination of employment medical, health, life insurance or other
post-retirement benefits with respect to Employees or Former Employees, except
to the extent of the continuation of health insurance coverage legally required
to be offered under COBRA or State COBRA.
(q) Since
January 1, 2008, neither the Company nor the ERISA Affiliates have (i) increased
the rate of compensation payable or to become payable to any of the salaried
Employees of the Company and its ERISA Affiliates, other than in the normal
course of business and consistent with past practice; (ii) increased any
benefits or rights under any Company Plan; or (iii) adopted any new plan,
program, policy or arrangement, which if it existed as of the Closing Date,
would constitute a Company Plan.
30
(r) Except
as set forth in Section 3.16(r) of the
Disclosure Schedule, neither the execution of this Agreement nor the
consummation of the transactions contemplated by this Agreement will (either by
themselves or in conjunction with any other event): (i) entitle any Employee,
Former Employee or other service provider of the Company or a ERISA Affiliate to
severance benefits or any other payment or (ii) accelerate the time of payment
or vesting, or increase the amount, of compensation due any such Employee or
service provider.
(s) No
person is, or will as a result of the transactions contemplated by this
Agreement become, entitled to any payment or benefit from or with respect to the
Company which constitutes a “parachute payment” within the meaning of Section
280G of the Code.
(t) Except
as set forth on Section 3.16(t) of the
Disclosure Schedule, the Company and the ERISA Affiliates do not maintain
any “nonqualified deferred compensation plans” within the meaning of Code
Section 409A. Except as set forth on Section 3.16(t) of the
Disclosure Schedule, each nonqualified deferred compensation plan that is
subject to Code Section 409A complies in form and in operation with paragraphs
(2), (3) and (4) of Code Section 409A and no amount thereunder is or may become
subject to Code Section 409A(1), based on the statutory requirements and the
existing regulations issued as of the date of execution of this
Agreement. Section 3.16(t) of the
Disclosure Schedule also identifies each such plan in which amounts were
deferred or became vested after 2004. Section 3.16(t) of the
Disclosure Schedule also identifies the amount of benefits payable to
each participant and beneficiary in each of the Company Plans that is a
nonqualified deferred compensation plan.
Section
3.17 Capitalization and Equity
Ownership. The
authorized equity securities of the Company consist of 1,500,000 shares of
common stock, no par value, of which 625,126 shares of common stock are issued
and outstanding, constitute the Company Shares and are held by the Sellers and
the ESOP in amounts listed in Schedule 1. The
Sellers and the ESOP are the record and beneficial owners and holders of the
Company Shares, free and clear of all Encumbrances, other than restrictions on
transfer under applicable state and federal securities Laws and preemptive
rights and/or rights of first refusal to acquire Company Shares. No
legend or other reference to any purported Encumbrance appears upon any
certificate representing Company Shares, other than restrictions on transfer
under applicable state and federal securities Laws and preemptive rights to
acquire Company Shares. All of the outstanding Company Shares have
been duly authorized and validly issued, and are fully paid and
non-assessable. Other than this Agreement and the Ancillary
Agreements, there are no Contracts relating to the issuance, sale, or transfer
of any Company Shares, and including, without limitation, the Company Shares
owned by the ESOP. None of the outstanding Company Shares were issued
in violation of the Securities Act or any other Law or any preemptive right
whether such right was granted by statute or contract. The Company
does not own or have a Contract to acquire any equity securities or other
securities of any Person or any direct or indirect equity or ownership interest
in any other business. True and complete copies of all agreements
relating to the ownership interest of the stockholders of the Company have been
provided to Purchaser, and such agreements have not been amended, modified or
supplemented, and there are no agreements to amend, modify or supplement such
agreements in any case from the form provided to Purchaser.
Section
3.18 Certain Agreements Affected
by the Acquisition. Neither
the execution and delivery of this Agreement and the Ancillary Agreements nor
the consummation of the transactions contemplated hereby or thereby will (a)
result in any payment (including severance, unemployment compensation, golden
parachute, bonus or otherwise) becoming due to any Employee, consultant or
independent contractor of the Company engaged in the conduct of the Business,
(b) increase any benefits otherwise payable by the Company to any Employee,
consultant or independent contractor engaged in the conduct of the Business, or
(c) result in the acceleration of the time of payment or vesting of any such
benefits of any Employee, consultant or independent contractor engaged in the
Business, except as provided in the Ancillary Agreements.
31
Section
3.19 Employee
Matters.
(a) Except
as set forth on Section 3.19(a) of the
Disclosure Schedule, since January 1, 2003, (i) there has been no federal
or state claim, including court claims, complaints or charges before a federal
or state administrative agency, based on sex, sexual or other harassment, age,
disability, race, national origin, religion or other discrimination, other
statutory claim, complaint or charge relating to employment, whether under
federal, state or local Law or ordinance, or any common law claim, including
claims of wrongful termination, and/or tort claims involving Employees, by any
Employee against the Company and there is no fact or circumstance known to the
Company that could reasonably be expected to give rise to such a complaint,
claim or charge or to result in any Action or Proceeding; and (ii) the Company
has not received any notice of any claim that it has not complied in any respect
with any Law relating to the employment of any of the Employees, including any
provisions thereof relating to wages, hours, collective bargaining, the payment
of social security and similar taxes, equal employment opportunity, employment
discrimination, reasonable accommodations, family or medical leave, immigration,
including IRCA, the WARN Act, employee safety, or that it is liable for any
arrearage of wages or any Tax or penalty for failure to comply with any of the
foregoing.
(b) There
are no outstanding, pending or, to the knowledge of the Company threatened: (i)
material claims, disputes or other controversies between the Company and any of
its Employees; (ii) unfair labor practice charges or other material complaints
or grievances against the Company in connection with its operation of the
Business; (iii) labor strikes, slowdowns, picketings, work stoppages or other
labor disputes against the Company affecting the operation of the Business; or
(iv) inspection or prosecution orders against the Business under any labor,
employment or occupational health and safety legislation and there is no basis
for any such action.
(c) The
Company has paid all amounts due to be paid to each Employee, former Employee,
current and former consultant, current and former independent contractor, and
current and former distributor, other than with respect to any equity interest
in the Company. The Company has not made any deductions from Employee
wages except as may be permitted by applicable Law.
(d) There
is no pending claim against the Company by any Employee under any workers’
compensation plan or policy or for long term disability under any long-term
disability plan. There is no controversy pending or threatened
between the Company and any Employee which has or could reasonably be expected
to result in an Action or Proceeding. The Company is not a party to
any collective bargaining agreement or other labor union contract nor does the
Company know of any activities or proceedings of any labor union or any other
Person(s) to organize any Employees. There has been no work stoppage,
strike or other concerted action by any Employees.
32
(e) Each
Employee engaged in the conduct of the Business is employed at
will. To the knowledge of the Company, no Employee is in violation of
any term of any employment contract, patent disclosure agreement,
non-competition agreement, or any restrictive covenant to a former employer
relating to the right of any such Employee to be employed by the Company, as the
case may be, because of the nature of the Business conducted by the Company or
to the use of trade secrets or proprietary information of others. No
Employee has given notice to the Company, and to the Company’s knowledge, no
Employee intends to terminate his or her employment with the
Company. Section 3.19(e) of the
Disclosure
Schedule lists each Employee under the heading “Employees,” each
consultant and independent contractor to the Company engaged in the conduct of
the Business under the heading “Consultants and Independent Contractors,” and
each temporary worker engaged in the conduct of the Business identified as
“Temporary”, and each such Person’s applicable position, and annual compensation
(listing separately salary, most recent annual bonus compensation and other most
recent annual incentive compensation) as of the date hereof. As of
the Closing Date, the Company will have a sufficient number of appropriately
trained employees of the Company to continue to conduct the Business as
presently conducted.
(f) To
the Company’s knowledge, no Employee, no consultant or independent contractor of
the Company or temporary worker who is engaged in the conduct of the Business is
obligated under any Contract or subject to any Order or Law that would interfere
with the conduct of the Business as currently conducted. To the
Company’s knowledge, neither the execution nor delivery of this Agreement, nor
the carrying on of the Business as presently conducted nor any activity of such
Employees or consultants in connection with the carrying on of the Business as
presently conducted, will conflict with or result in a breach of the terms,
conditions or provisions of, constitute a default under, or trigger a condition
precedent to any rights under any Contract under which any of such Employees,
consultants or independent contractors are now bound.
(g) The
Company has completed I-9 forms for all Employees pursuant to the Immigration
Reform and Control Act thereby confirming the work eligibility and identity of
each Employee. All filings and documents required under the
immigration laws with regard to any Employees have been filed, maintained and
retained. Neither the Company, nor any Person acting on its behalf
has misrepresented a material fact to gain an immigration benefit by, for or on
behalf of an Employee.
(h) The
Company has informed all Employees of their rights under the Family and Medical
Leave Act (“FMLA”) or
Laws relating to family and medical leave. The Company has provided
all eligible Employees with FMLA leave and has returned all Employees taking
FMLA leave to the same or a substantially similar job following any FMLA
leave.
(i) Except
as disclosed in Section 3.19(i) of the
Disclosure Schedule, all Employees of the Company are employed at-will,
such that either the Company or the Employee may terminate the employment
relationship at any time for any reason.
33
Section
3.20 Interested Party
Transactions.
(a) Except
as disclosed in Section 3.20(a) of the
Disclosure Schedule, there are no Contracts, arrangements,
understandings, transfers of assets or liabilities or other commitments or
transactions, whether or not entered into in the ordinary course of business
consistent with past practice, to or by which both the Company and any Affiliate
of the Company are parties and that are currently pending or in effect and
relate to or affect the Business or any of the Assets and Properties of the
Company or affect any Liabilities of the Company.
(b) Each
Contract, arrangement, understanding, transfer of assets or liabilities or other
commitments or transactions set forth or required to be set forth in Section 3.20(a) of the
Disclosure Schedule was entered into, or incurred, as the case may be, on
terms and conditions as favorable to the Company as would have been obtainable
by the Company in a comparable arm’s-length transaction with a Person other than
an Affiliate of the Company.
(c) No
stockholder, officer, director, partner, member or Employee of the Company (i)
owns, directly or indirectly, on an individual or joint basis, any interest in
(A) any Assets and Properties of the Company or (B) any Person that is a
supplier, customer or competitor of the Company in connection with the Business
(other than through the ownership of one percent (1%) or less of any class of
securities registered under the Exchange Act); (ii) serves as an officer,
director or employee of any Person that is a supplier, customer or competitor of
the Business; or (iii) except as set forth on Section 3.20(c) of the
Disclosure Schedule, has received any loan from or is otherwise a debtor
of, or made any loan to or is otherwise a creditor of, the Company.
Section
3.21 Insurance.
Section 3.21 of the
Disclosure Schedule contains a complete and correct list of all insurance
policies and bonds maintained by the Company related to any of the Assets and
Properties of the Company, the Liabilities of the Company or the
Business. There is no claim pending under any such policies or bonds
as to which coverage has been questioned, denied or disputed by the underwriters
of such policies or bonds other than customary reservation of rights
provisions. Each policy listed in Section 3.21 of the
Disclosure Schedule is valid and binding and in full force and effect,
all premiums due and payable under all such policies and bonds have been paid
and the Company is otherwise in compliance with the terms of such policies and
bonds. Neither the Company nor the Person to whom such policy has
been issued has received any written notice of cancellation or termination of,
or premium increase with respect to, any such policies.
Section
3.22 Books and Records.
The Books
and Records of the Company are complete and correct in all material respects and
have been maintained in accordance with sound business practices. The
Company’s minute books contain a complete and accurate summary of all meetings
of directors, stockholders and members, as applicable, or actions by written
consent that relate to the Business or the Assets and Properties of the Company,
through the date of this Agreement, and reflect all transactions involving the
Business or Assets and Properties of the Company referred to in such minutes
accurately in all material respects. Prior to the execution of this
Agreement, the Company has delivered to Purchaser true copies of its Certificate
of Incorporation and Bylaws, both as amended through the date of this Agreement,
and true copies of all actions by written consent that relate to the Business or
the Assets and Properties through the date of this Agreement.
34
Section
3.23 Bank
Accounts.
Section 3.23 of the
Disclosure Schedule sets forth the name of each bank or similar entity in
which the Company has an account, lock box or safe deposit box, the account
number of all accounts held by the Company, and the names of the persons
authorized to draw thereon or have access thereto.
Section
3.24 Brokers’ and Finders’ Fees;
Third Party Expenses Neither
the Company nor any Seller has incurred, nor will incur, directly or indirectly,
any liability for brokerage, finders’, or financial advisor’s fees or agents’
commissions or investment bankers’ fees or any similar charges, fees or
commissions in connection with this Agreement or any transaction contemplated by
this Agreement.
Section
3.25 Customers,
Suppliers and
Sales Representatives.
(a) Section 3.25(a)(i) of the
Disclosure Schedule lists each customer of the Business that individually
accounts for more than One Hundred Thousand Dollars ($100,000) of the consolidated
gross revenues of the Business during the twelve (12) month period ended on
December 31, 2007, on the basis of revenues collected. Section 3.25(a)(ii) of the
Disclosure Schedule lists the ten (10) largest suppliers of the Business
on the basis of cost of goods or services purchased during the twelve (12) month
period ended on December 31, 2007. Section 3.25(a)(iii) of the
Disclosure Schedule lists all sales representatives of the
Company. To the Company’s knowledge, no such customer, supplier or
sales representative is threatened with bankruptcy or insolvency.
(b) No
(i) customer required to be disclosed in Section 3.25(a)(i) of the
Disclosure Schedule, (ii) supplier required to be disclosed in Section 3.25(a)(ii) of the
Disclosure Schedule or (iii) sales representative required to be
disclosed in Section
3.25(a)(iii) of the Disclosure Schedule, has ceased or materially
reduced, canceled or otherwise terminated, or made any written threat to the
Company to cancel or otherwise terminate its relationship with the Company
relating to the Business, or materially decreased its services or supplies to
the Company, in the case of any such supplier or sales representative, or its
usage of any service or purchase of any product of the Business, in the case of
such customer or sales representative (as applicable), and, to the Company’s
knowledge, no supplier, sales representative, or customer intends to cancel or
otherwise terminate its relationship with the Company or to materially decrease
its services or supplies to the Company or its usage of the services or products
of the Company or to seek a reduction in the price (or a modification of any
other material term) on which it purchases services or products of the Business
or, in the case of sales representatives, sells products of the
Company. Each Contract between the Company and any customer, supplier
or sales representative is identified in the appropriate subsection of Section 3.25(a) of the
Disclosure Schedule.
(c) Each
(i) customer required to be disclosed in Section 3.25(a)(i) of the
Disclosure Schedule, (ii) supplier required to be disclosed in Section 3.25(a)(ii) of the
Disclosure Schedule or (iii) sales representative required to be
disclosed in Section
3.25(a)(iii) of the Disclosure Schedule has transacted business with the
Company and otherwise has acted substantially in accordance with the terms of
its Business Contract consistent with the established course of conduct or, to
the extent there is no Business Contract, its course of performance with the
Company over the twelve (12) months preceding the date of this
Agreement. Each such customer, supplier or sales representative has
not sought in writing, or indicated in writing any intention to seek, a material
reduction in the prices it currently pays for products and services of the
Company or material increase in the price it currently charges the Company for
supplier products and services or sales representatives services, as the case
may be, or any other material modification of any payment term or other material
term applicable to its purchases of products and services of the Company or
sales to the Company or sales to the Company’s customers, as
applicable.
35
Section
3.26 Contracts and
Licenses.
(a) Section 3.26(a) of the
Disclosure Schedule contains a true and complete list of each of the
Business Contracts, Business Licenses, Real Property Leases and Personal
Property Leases pursuant to which the Company will either receive payments in
excess of $100,000 or make payments in excess of $50,000, in each case in any
period of twelve consecutive months, true and complete copies of which, together
with all amendments and supplements thereto and all waivers of any terms
thereof, have been delivered to Purchaser prior to the execution of this
Agreement.
(b) Except
for the Contracts and Licenses described in Section 3.26(b) of the
Disclosure Schedule, the Company is not a party to or bound by any
material Contract or License, including:
(i) any
distributor, agency, advertising agency, marketing, manufacturer’s or
representative sales Contract related to the Business;
(ii) any
continuing Contract for the purchase of materials, supplies, equipment or
services for use in connection with the Business which is not subject to
cancellation by the Company, or which is subject to cancellation by the other
party thereto on sixty (60) or fewer days’ notice;
(iii) any
Business Contract or any Contract otherwise binding upon any of the Assets and
Properties of the Company or relating to any of the Liabilities of the Company
that had or would reasonably be expected to have, either individually or in the
aggregate with any other similar Contracts, a Material Adverse Effect on the
Business;
(iv) any
Contract related to the conduct of the Business that expires or may be renewed
at the option of any Person other than the Company so as to expire more than one
year after the date of this Agreement;
(v) any
Contract related to the conduct of the Business that (a) automatically
terminates or provides for termination by any Person other than the Company upon
consummation of the transactions contemplated by this Agreement or (b) contains
any covenant or other provision which limits the Company’s ability to compete
with any Person in any line of business comprising the Business or in any
market, area, jurisdiction or territory;
36
(vi) any
trust indenture, mortgage, promissory note, loan agreement or other Contract for
the borrowing of money, any currency exchange, commodities or other hedging
arrangement or any leasing transaction related to the conduct of the Business or
binding on the Assets and Properties of the Company of the type required to be
capitalized in accordance with GAAP;
(vii) any
Contract for capital expenditures related to the conduct of the Business;
or
(viii)
any Contract of guarantee, support, indemnification, assumption or endorsement
of, or any similar commitment with respect to, the obligations, or Liabilities
of the Company secured by any of the Assets and Properties of the
Company.
(c) Except
as set forth in Section 3.26(c) of the
Disclosure Schedule, all Contracts and Licenses set forth in Section 3.26(b) of the
Disclosure Schedule, and all transactions in which the Company has
engaged with a customer, supplier or sales representative of the Company, have
utilized U.S. Dollars as the underlying currency.
Section
3.27 No Breach of Business
Contracts or
Business Licenses.
Except as
set forth on Section
3.27 of the Disclosure Schedule, all of the Business Contracts, Business
Licenses, Real Property Leases and Personal Property Leases are in written
form. The Company has performed in all material respects all of the
obligations required to be performed by it and is entitled to all benefits
under, and is not in default, and is not alleged in writing to be in default, in
respect of any Business Contract, Business License, Real Property Lease and
Personal Property Lease. Each of the Business Contracts, Business
Licenses, Real Property Leases and Personal Property Leases is in full force and
effect, and there exists no default or event of default or event, occurrence,
condition or act, with respect to the Company or, to the Company’s knowledge,
with respect to the other contracting party, which, with the giving of notice,
the lapse of time or the happening of any other event or condition, would become
a default or event of default under any Business Contract, Business License,
Real Property Lease or Personal Property Lease.
Section
3.28 Third Party
Consents.
Section 3.28 of the
Disclosure Schedule lists (a) all Business Contracts, Business Licenses,
Real Property Leases and Personal Property Leases that require a novation or
consent in connection with the transactions contemplated by this Agreement,
prior to the Closing Date and (b) every Business Contract, Business License,
Real Property Lease and Personal Property Lease which, if no novation occurs or
if no consent is obtained, would adversely affect the Company’s ability to
operate the Business in the same manner as the Business was operated prior to
the Closing Date.
Section
3.29 Solvency.
The
Company is, and at the time of the consummation of the transactions contemplated
herein will be, solvent. For purposes of this Agreement, “solvent”
shall mean that, on the date specified (a) the fair value of the Assets and
Properties of the Company shall be greater than the total amount of its
Liabilities, including those arising under any Law, Order, Contract,
arrangement, commitment or undertaking; (b) the present fair salable value of
the Company’s Assets and Properties is not less than the amount that will be
required to pay the probable debts and liabilities of the Company on its debts
as they become absolute and matured in accordance with their stated terms; (c)
the Company does not intend to, and does not believe that it will, incur debts
or liabilities beyond its ability to pay as such debts and liabilities mature;
and (d) the Company is not engaged in, and is not about to be engaged in, a
business or a transaction for which its property would constitute unreasonably
small capital.
37
Section
3.30 Absence of Certain Business
Practices. Neither
the Company nor any member of the governing board of the Company, officer,
Employee, agent, or representative of the Company, or any other Person acting on
behalf of the Company, acting alone or together, has (i) received, directly or
indirectly, any rebates, payments, commissions, promotional allowances or any
other economic benefits, regardless of their nature or type, from any vendor,
governmental employee or other Person with whom the Company has done business
directly or indirectly, or (ii) directly or indirectly, offered, given or agreed
to offer or give any gift or similar benefit to any vendor, governmental
employee or other Person who is or may be in a position to help or hinder the
Business (or assist the Company in connection with any actual or proposed
transaction) which, in the case of either clause (i) or clause (ii) above, would
reasonably be expected to subject the Company to damage or penalty in any civil,
criminal or governmental Action or Proceeding.
Section
3.31 Disclosure of Certain
Financial Relationships. The
Company has disclosed to Purchaser any and all financial relationships (whether
or not memorialized in a writing) that the Company has had with a physician or
an immediate family member of a physician. For purposes of this
Section 3.31, the term “financial relationship” has the meaning set forth in 42
U.S.C. § 1395nn.
Section
3.32 Real Property.
The
Company does not own any real property and does not lease any real property
other than pursuant to the Real Property Leases.
Section
3.33 Names.
The
Company has not transacted the Business of the Company under any name other than
the names set forth in Section 3.33 of the
Disclosure Schedule.
Section
3.34 Competition.
The
Company has not entered into any agreement with any Person or entity relating to
the Business or the Assets that contains any prohibition or restriction of
competition or solicitation of customers.
Section
3.35 Representations Complete.
None of
the representations or warranties made by the Sellers or the Company herein, and
none of the statements, representations or warranties contained in the
Disclosure Schedule or in any certificate, list or other writing furnished to
Purchaser by the Company and the Sellers pursuant to this Agreement or any of
the Ancillary Agreements, when all such documents are read together in their
entirety, contain any untrue statement of a material fact, or omit to state any
material fact necessary in order to make the statements contained herein or
therein, in the light of the circumstances under which made, not misleading. It
is the explicit intent of each party hereto that the Sellers and the Company are
making no representations or warranties except as set forth in this Agreement,
the Ancillary Agreements, the Disclosure Schedule, and the certificates,
documents and instruments delivered in connection herewith or therewith, and
except further that nothing in this sentence shall be construed to absolve the
Sellers or the Company from liability for fraud or intentional
misrepresentation.
38
ARTICLE
IV
REPRESENTATIONS
AND WARRANTIES OF THE SPECIAL FIDUCIARY AND TRUSTEE
As an
inducement for the Purchaser to enter into this Agreement and consummate the
transactions contemplated herein, the Special Fiduciary and Trustee hereby
represents and warrants to Purchaser that the statements set forth in this Article IV are true
and correct.
Section
4.01 Organization and
Qualification.
The
Special Fiduciary and Trustee is a trust company duly organized, validly
existing and in good standing under the laws of the Commonwealth of
Massachusetts, with all requisite corporate power and authority to execute and
deliver this Agreement.
Section
4.02 Authority.
The
execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby have been duly and validly authorized and
approved by the Special Fiduciary and Trustee on behalf of the ESOP, and no
other act or consent of any other person is necessary to authorize the Special
Fiduciary and Trustee’s execution and delivery of this Agreement and
consummation of the transactions contemplated by this Agreement and the
Ancillary Agreements. This Agreement and any Ancillary Agreement to
which the ESOP or Special Fiduciary and Trustee is a party, has been duly and
validly executed and delivered by the Special Fiduciary and Trustee and
constitutes a valid and binding agreement of the ESOP and of the Special
Fiduciary and Trustee in its capacity as trustee of the ESOP.
Section
4.03 No
Conflict.
The
execution and delivery of this Agreement and any Ancillary Agreement to which
the ESOP or Special Fiduciary and Trustee is a party and the consummation of the
transactions contemplated hereby or thereby will not: (i) violate any
provision of the charter or by-laws of the Special Fiduciary and Trustee or the
ESOP; (ii) violate any statute, rule, regulation, order, injunction or decree of
any court or governmental agency or instrumentality applicable to the Special
Fiduciary and Trustee; or (iii) violate any agreement or instrument by which the
Special Fiduciary and Trustee may be bound.
39
Section
4.04 Status of Special Fiduciary
and Trustee.
The
Special Fiduciary and Trustee (i) has received copies of the agreements
constituting the ESOP, (ii) is properly bonded or exempt from such bond in
accordance with the requirements of Section 412 of ERISA, and (iii) is a
fiduciary within the meaning of Section 3(21) of ERISA with respect to the
ESOP. The Special Fiduciary and Trustee has been duly appointed as
trustee of the ESOP in accordance with the terms thereof and applicable
law. The Special Fiduciary and Trustee is the sole trustee of the
ESOP with the authority to act on behalf of the ESOP with respect to the matters
contemplated by this Agreement.
Section
4.05 Counsel to Special Fiduciary
and Trustee.
The
Special Fiduciary and Trustee has retained independent legal counsel
knowledgeable in matters regarding fiduciary responsibilities under ERISA and
the Code, and has retained a qualified independent appraiser to advise the
Special Fiduciary and Trustee regarding the transactions contemplated by this
Agreement.
Section
4.06 Broker’s
Fee.
No
broker, finder or investment banker is entitled to any brokerage, finder’s or
other fee or commission in connection with the transactions contemplated by this
Agreement based upon arrangements made by or on behalf of the Special Fiduciary
and Trustee or the ESOP. Atlantic Management Company, Inc. will
receive a fee in connection with its issuance of a fairness opinion in
connection with the transactions contemplated by this Agreement.
Section
4.07 Claims Against the
Company.
Except
for unpaid fees owed to the Special Fiduciary and Trustee from the Company for
services rendered in the Special Fiduciary and Trustee’s capacity as a trustee
of the ESOP and fees related to cash management and depository services, the
Special Fiduciary and Trustee has no claims or causes of action against the
ESOP, the Company, or any of the Affiliates at law or in equity, whether accrued
or unaccrued, fixed or contingent.
Section
4.08 Equity
Ownership.
The ESOP
owns 87,426 shares of Company common stock. The ESOP is the record
and beneficial owner and holder of such shares, free and clear of all
Encumbrances, other than restrictions on transfer under applicable state and
federal securities Laws and preemptive rights and/or rights of first refusal to
acquire Company Shares. No legend or other reference to any purported
Encumbrance appears upon any certificate representing such shares, other than
restrictions on transfer under applicable state and federal securities Laws and
preemptive rights to acquire such shares. Other than this Agreement
and the Ancillary Agreements, the Special Fiduciary and Trustee is not a party
to any Contracts relating to the issuance, sale, or transfer of such
shares.
40
ARTICLE
V
REPRESENTATIONS
AND WARRANTIES OF PURCHASER
As an
inducement for the Sellers, Special Fiduciary and Trustee and the Company to
enter into this Agreement and consummate the transactions contemplated herein,
Purchaser hereby represents and warrants to the Sellers, Special Fiduciary and
Trustee and the Company that the statements set forth in this Article V are true
and correct.
Section
5.01 Organization, Standing and
Power. Purchaser
is a corporation duly organized, validly existing and in good standing under the
Laws of the state of its incorporation. Purchaser has the corporate
power and authority to own, use, license, lease and operate its properties and
to carry on its business as it is now being conducted and is duly qualified,
licensed or admitted to do business and is in good standing in each jurisdiction
in which the ownership, use, licensing, leasing or operation of its properties,
or the conduct or nature of its business, makes such qualification, licensing or
admission necessary.
Section
5.02 Authority.
Purchaser
has all requisite corporate power and authority to enter into, execute and
deliver this Agreement and the other Ancillary Agreements to which it is a
party, to consummate the transactions contemplated hereby and thereby, and to
perform its obligations hereunder and thereunder. The execution and
delivery of this Agreement and the Ancillary Agreements, and the consummation of
the transactions contemplated hereby and thereby, have been duly and validly
authorized by all necessary corporate action on the part of
Purchaser. This Agreement has been, and the Ancillary Agreements to
which Purchaser is a party will be, duly executed and delivered by
Purchaser. This Agreement constitutes, and the other Ancillary
Agreements to which Purchaser is a party, when executed and delivered as
contemplated by this Agreement, will constitute, assuming the due authorization,
execution and delivery by each of the other parties hereto and thereto, valid
and binding obligations of Purchaser, enforceable against Purchaser in
accordance with their respective terms, except as such enforceability may be
limited by applicable bankruptcy and insolvency Laws, the rights of creditors
generally, and equitable remedies whether asserted in actions at Law or in
equity.
Section
5.03 No Conflict.
The
execution and delivery by Purchaser of this Agreement and the Ancillary
Agreements to which Purchaser is a party do not, and the consummation by
Purchaser of the transactions contemplated hereby and thereby do not and will
not (i) conflict with or violate any provision of the Certificate of
Incorporation or Bylaws of Purchaser, (ii) conflict with or violate in any
material respect any Law applicable to Purchaser or by which any of its Assets
and Properties is bound, or (iii) result in any breach of or constitute a
default (or an event which with the giving of notice or lapse of time or both
could reasonably be expected to become a default) under, or give to others any
right of termination, amendment, acceleration or cancellation of, any material
note, bond, mortgage, indenture, Contract, agreement, lease, license, permit,
franchise or other instrument or obligation to which Purchaser is a party or by
which any of its Assets and Properties is bound so as to impair the ability of
Purchaser to carry out its obligations under, or to prevent or delay the
completion of the transactions contemplated by, this Agreement.
41
Section
5.04 Litigation; Regulatory
Compliance.
There is
no private or governmental Action or Proceeding pending, or, to the knowledge of
Purchaser, threatened against Purchaser, and no judgment, decree or Order
applicable to Purchaser, that could reasonably be expected to prevent, enjoin,
alter or delay any of the transactions contemplated by this Agreement or the
Ancillary Agreements.
Section
5.05 No Further
Representations.
Notwithstanding
anything to the contrary contained in this Agreement, it is the explicit intent
of each party hereto that Purchaser is making no representation or warranty
whatsoever, express or implied, except as set forth in this Article V, the
Ancillary Agreements, and the certificates, documents and instruments delivered
in connection herewith or therewith, and except further that nothing in this
sentence shall be construed to absolve Purchaser from liability for fraud or
intentional misrepresentation.
ARTICLE
VI
COVENANTS
AND AGREEMENTS
Section
6.01 Conduct of Business by the
Company Pending the Closing.
Each
Seller agrees that between the date of this Agreement and the Closing Date,
unless Purchaser shall otherwise agree in writing, each Seller shall, and shall
cause the Company to: (w) conduct the Business of the Company only in
the ordinary course consistent with past practice; (x) pay and perform any
of the Company’s debts, obligations and Liabilities relating to the Business and
the Assets and Properties of the Company as and when due and the Contracts and
other commitments relating to the Business and the Assets and Properties of the
Company in accordance with the terms and provisions thereof; (y) comply
with all Laws and Orders that may be applicable to any of the Business or the
Assets and Properties of the Company; and (z) use its best efforts to keep
available the services of the Employees and to preserve current relationships
with corporate partners, customers, suppliers, manufacturers and other persons
doing business with the Company in order to preserve substantially intact the
Business of the Company. By way of amplification and not limitation,
each Seller shall not, and shall cause the Company not to, between the date of
this Agreement and the Closing Date, directly or indirectly, take, agree to take
or allow, cause or permit any other Person to take, agree, agree to take or
allow, cause or permit any of the following actions without the prior written
consent of Purchaser:
(a) sell,
pledge, dispose of, grant, transfer, lease, license, guarantee or encumber, or
authorize the issuance, sale, pledge, disposition, grant, transfer, lease or
license of, or any Encumbrance on, the Company and any of the Assets and
Properties of the Company except in the ordinary course of business consistent
with past practice where immaterial (both individually and in the aggregate) in
both amount and significance;
(b) acquire,
other than in the ordinary business of the Company, any Assets and Properties,
or acquire or make any arrangement to acquire any Inventory in excess of the
amount of Inventory which, together with Inventory existing as of the date
hereof, is necessary to fulfill firm purchase orders with delivery dates prior
to the Closing Date, and obligations of the Company under long-term purchase
contracts with delivery dates prior to the Closing Date, which, in each case,
the Company is responsible for fulfilling prior to the Closing or which the
Company will be responsible for fulfilling after the Closing Date;
42
(c) engage
with any Person in any merger, consolidation or other business combination
transaction;
(d) violate,
breach or default under in any material respect, or take or fail to take any
action that (with or without notice or lapse of time or both) would constitute a
material violation or breach of, or default under, any term or provision of any
Business Contract, Business License, Real Property Lease or Personal Property
Lease; or terminate, cancel or request any material change in, or agree to any
material change in, any Business Contract, Business License, Real Property Lease
and Personal Property Lease; or enter into or amend any Contract, that would
constitute a Business Contract, Business License, Real Property Lease and
Personal Property Lease and that, if fully performed, would not be permitted
under this Section 6.01;
(e) make
or authorize any capital expenditure with respect to the Business of the
Company, other than capital expenditures in the ordinary course of business
consistent with past practice that have been budgeted for the fiscal period in
question and have heretofore been disclosed in writing to
Purchaser;
(f) (i)
increase the compensation payable or to become payable to, or the rate of
vacation accrual of, any of the Employees; (ii) grant any options to, grant any
rights to severance or termination pay to, or enter into any employment or
severance agreement which provides benefits upon a change in control of the
Company that would be triggered by the transactions contemplated by this
Agreement or by the Ancillary Agreements with, any Employee who is not currently
entitled to such benefits from the transactions contemplated by this Agreement;
(iii) establish, adopt, enter into or amend any Benefit Plan, agreement, trust,
fund, policy or arrangement for the benefit of any Employee except to the extent
required by applicable Law; (iv) enter into or amend any Contract, commitment or
arrangement with any of the Employees; or (v) make any representation or
promise, oral or written, to any Employee concerning any Benefit Plan, except
for statements as to the rights or accrued benefits of any Employee under the
terms of any Benefit Plan in effect as of the date hereof;
(g) incur,
cancel, pay, prepay, discharge or satisfy any claim or Liability other than in
the ordinary course of business;
(h) engage
in any transaction with respect to any of the Assets and Properties or the
Business of the Company with any officer, director, Affiliate or Associate of
the Company, or any Associate of any such officer, director or Affiliate, either
outside the ordinary course of business consistent with past practice or other
than on an arm’s-length basis;
(i) make
any change with respect to the Company’s accounting policies, principles,
methods or procedures, including revenue recognition policies, other than as
required by GAAP;
(j) make
any material Tax election or settle or compromise any material Tax liability
relating to the Business of the Company or any of the Assets and Properties of
the Company;
43
(k) permit
any insurance policy naming the Company as a beneficiary or a loss payee and
relating to the Business or any of the Assets or Properties of the Company to be
cancelled, terminated or not renewed, except in the ordinary course of
business;
(l) maintain
the Books and Records of the Company relating either to the Business or to any
of the Assets and Properties of the Company in a manner not consistent with past
business practices;
(m) take
any action which would adversely affect the goodwill of the Company’s suppliers,
manufacturers, customers, licensees and others with whom it has business
relations in connection with the Business of the Company in any material
respect; or
(n) authorize
or enter into any Contract or otherwise make any commitment to do any of the
foregoing or to take any action which would make any of the representations or
warranties in Article
III
untrue or incorrect in any material respect or prevent any Seller or the
Company from performing or cause such Seller or the Company not to perform its
covenants and agreements herein or result in any of the conditions to the
Closing set forth herein not being satisfied.
Section
6.02 Notice of Certain
Events.
The
Company, each Seller, and the Special Fiduciary and Trustee shall give prompt
notice to the Purchaser of: (i) any notice or other
communication from any Person received by it alleging that any consent, waiver
or approval of such Person is or may be required in connection with any of the
transactions contemplated by this Agreement; (ii) any notice or other
communication received by it from any Governmental Entity or arbitrator or
mediator in connection with any of the transactions contemplated by this
Agreement or the Ancillary Agreements; (iii) any Action or Proceeding
commenced or, to its knowledge, threatened against, relating to or involving or
otherwise affecting Purchaser, such Seller or the Company that relates to the
Business of the Company or may affect the consummation of any of the
transactions contemplated by this Agreement or the Ancillary Agreements (and
with respect to the Special Fiduciary and Trustee, only in the event the Special
Fiduciary and Trustee is a party to such Action or Proceeding or as to which
Xxxxxxx Xxxxxx or Xxxx XxXxxxx have actual knowledge of such Action or
Proceeding); (iv) the occurrence of a default or event that, with the
giving of notice or lapse of time or both, will become a default under any
Business Contract, Business License, Real Property Lease and Personal Property
Lease applicable to the Business (and with respect to the Special Fiduciary and
Trustee, only to the extent the Special Fiduciary and Trustee is a party to such
Business Contract, Business License, Real Property Lease and Personal Property
Lease); and (v) any change, event or occurrence that could reasonably be
expected to render any of the representations and warranties given under Article
III and Article IV, respectively, untrue or incorrect in any material respect
(limited as to the Special Fiduciary and Trustee to representations and
warranties under Article IV), or to materially delay or materially impede the
ability of any Seller, the Special Fiduciary and Trustee or the Company to
perform its respective obligations pursuant to this Agreement and the other
transactions contemplated by this Agreement or the Ancillary
Agreements.
44
Section
6.03 Access to Information;
Confidentiality.
(a) Except
as required pursuant to any confidentiality agreement or similar agreement or
arrangement to which a Seller or any of its Affiliates is a party or pursuant to
applicable Law or the regulations or requirements of any regulatory organization
with whose rules such Seller is required to comply, between the date of this
Agreement and the Closing Date, each Seller shall (i) provide upon prior
notice to Purchaser (and its officers, directors, employees, accountants,
consultants, legal counsel, financial advisers, agents and other representatives
(collectively, “Representatives”)) access at
reasonable times to its officers, Employees, agents, properties, offices and
other facilities and to the Books and Records thereof (and the Special Fiduciary
and Trustee shall provide access at reasonable times to the Books and Records in
its possession that relate to the ESOP), and (ii) furnish promptly such
information concerning the Business, Contracts, Assets and Properties,
Liabilities and personnel as Purchaser or its Representatives may reasonably
request. No investigation conducted pursuant to this Section 6.03
shall affect or be deemed to modify any representation or warranty made in this
Agreement.
(b) The
parties hereto shall comply with, and shall cause their respective
Representatives to comply with, all of their respective obligations under the
Confidentiality Agreement with respect to the information disclosed pursuant to
this Section 6.03 or
pursuant to the Confidentiality Agreement, including, but not limited to, upon
request, the delivery or destruction of all tangible materials containing or
embodying such party’s Restricted Information (as that term is defined in the
Confidentiality Agreement), together with a certificate executed by the
returning party certifying that all such materials in its possession have been
returned or destroyed.
Section
6.04 No Solicitation of
Transactions.
From the
date hereof and until the earlier of the Closing Date or termination of this
Agreement, each Seller and the Special Fiduciary and Trustee shall not take, nor
shall it permit any of its Representatives, Affiliates or Associates to take,
directly or indirectly, any action to solicit, negotiate, assist or otherwise
facilitate or encourage (including by furnishing confidential information with
respect to the Business of the Company or permitting access to the Assets and
Properties or Books and Records of the Company) any offer, proposal, inquiry or
request for information from any Person concerning the direct or indirect
acquisition of the Business of the Company or any of the Assets and Properties
of the Company by any Person (an “Alternate Transaction”) other
than Purchaser. If a Seller or the Special Fiduciary and Trustee or
any of their Representatives, Affiliates or Associates receives from any Person
any such offer, proposal, inquiry or request for information, such Seller or the
Special Fiduciary and Trustee shall promptly advise such Person, by written
notice, of the terms of this Section 6.04 and
shall immediately, orally and in writing, advise Purchaser of such offer,
proposal, inquiry or request and deliver a copy of such notice to
Purchaser. Any violation of the restrictions set forth in this Section 6.04 by
any Representative, Affiliate or Associate of a Seller or the Special Fiduciary
and Trustee shall be deemed to be a breach of this Section 6.04 by
such Seller or the Special Fiduciary and Trustee. Any notice required
to be delivered pursuant to this Section 6.04 shall
include the identity of the Person making such offer, proposal, inquiry request,
and the terms of such offer, proposal, inquiry or request, and shall keep
Purchaser apprised, on a current basis, of the status of such offer, proposal,
inquiry or request. Each Seller and the Special Fiduciary and Trustee
shall immediately cease and cause to be terminated (and each Seller and the
Special Fiduciary and Trustee hereby represents and warrants that it has the
legal and contractual right, without liability of any sort, to cease and cause
to be terminated) all existing discussions or negotiations with any Persons
conducted heretofore with respect to any such offer, proposal, inquiry or
request. Each Seller and the Special Fiduciary and Trustee shall not
release any third party from, or waive any provision of, any confidentiality or
standstill agreement to which such third party is a party.
45
Section
6.05 Financial Statements and
Reports.
(a) As
promptly as practicable and in any event no later than ten (10) days after the
end of each calendar month and fifteen (15) days after the end of each fiscal
quarter ending after the date hereof and before the Closing Date, Sellers shall
deliver to Purchaser true and complete copies of the unaudited income statements
for the fiscal quarter or month and the portion of the fiscal year then ended
(in the case of any such fiscal quarter and calendar month), together with the
notes, if any, relating thereto, which income statements shall be prepared on
the same basis as the financial statements delivered pursuant to Section
3.06. Upon delivery of any income statement pursuant to this Section
6.05(a), an unaudited balance sheet dated as of the most recent month then ended
shall also be provided to Purchaser with respect to the Company.
(b) As
promptly as practicable, Sellers shall deliver to Purchaser true and complete
copies of such other financial statements, reports and analyses relating to the
Business or any of the Assets and Properties of the Company as may be prepared
by the Company or reasonably requested by Purchaser.
(c) As
promptly as practicable, Sellers shall deliver to Purchaser copies of all
License applications and other filings made by the Company in connection with
the operation of the Business of the Company after the date hereof and before
the Closing Date with any Governmental Entity (other than routine, recurring
filings made in the ordinary course of business consistent with past
practice).
Section
6.06 Delivery of Books and
Records; Removal of Property.
(a) On
the Closing Date, Sellers: (i) shall deliver to Purchaser at the site of the
Closing or at the site of the Company, copies or originals of all of the Real
Property Leases, the Personal Property Leases, the Business Contracts and the
Business Licenses, and shall make available to Purchaser at the locations at
which the Business is conducted, all of the other Books and Records of the
Company (and the Special Fiduciary and Trustee shall provide copies of all Books
and Records in its possession that relate to the ESOP), and (ii) shall deliver
or make available to Purchaser at the locations at which the Business of the
Company is conducted all other Assets and Properties of the
Company. If at any time after the Closing a Seller discovers in
such Seller’s possession or under such Seller’s control any other Books and
Records or other Assets and Properties of the Company, such Seller shall
forthwith deliver such Books and Records or other Assets and Properties of the
Company to Purchaser. If at any time after the Closing the Special
Fiduciary and Trustee discovers in its possession or under its control any other
Books and Records that relate to the ESOP, the Special Fiduciary and Trustee
shall forthwith deliver copies of such Books and Records to
Purchaser. Except as may otherwise specifically be required by this
Agreement, the documents and analyses prepared by the Special Fiduciary and
Trustee solely for its own use and other internally prepared documents of the
Special Fiduciary and Trustee solely for its own use are excluded from the
operation of this Section 6.06(a).
46
(b) Other
than as set forth in Section 6.06(b) of the Disclosure
Schedule, all Assets and Properties located on the premises of the
Company are Assets and Properties of the Company. Sellers and the
Special Fiduciary and Trustee may remove only the Assets and Properties
disclosed in Section
6.06(b) of the Disclosure Schedule from the premises of the Company at
anytime. However, such removal shall be at the sole cost and risk of
Sellers or the Special Fiduciary and Trustee, including risk of loss and damage
to such assets and properties. Purchaser shall have no liability to a
Seller or the Special Fiduciary and Trustee with respect to such removal and
transportation. Each Seller and the Special Fiduciary and Trustee
shall be responsible for all repairs to the premises of the Company due to
damage caused in connection with the removal of such assets and
properties.
Section
6.07 Notice and
Cure.
(a) Each
Seller and the Special Fiduciary and Trustee shall notify Purchaser in writing
of, and shall contemporaneously provide Purchaser with true and complete copies
of any and all information or documents relating to, and shall use all
commercially reasonable efforts to cure before the Closing, any event,
transaction or circumstance, as soon as practicable after it becomes known to
such Seller or the Special Fiduciary and Trustee (and as it relates to the
Special Fiduciary and Trustee, only as it relates to the ESOP), occurring after
the date of this Agreement that causes or may cause any covenant or agreement of
such Seller or the Special Fiduciary and Trustee under this Agreement to be
breached or that renders or may render untrue in any material respect any
representation or warranty of such Seller or the Special Fiduciary and Trustee
contained in this Agreement as if the same were made on or as of the date of
such event, transaction or circumstance. Each Seller and the Special
Fiduciary and Trustee also shall notify Purchaser in writing of, and shall use
all commercially reasonable efforts to cure, before the Closing, any violation
or breach, as soon as practicable after it becomes known to such Seller or
Special Fiduciary and Trustee, of any representation, warranty, covenant or
agreement made by such Seller or the Special Fiduciary and Trustee in this
Agreement, whether occurring or arising before, on or after the date of this
Agreement. No notice given pursuant to this Section 6.07(a)
shall have any effect on the representations, warranties, covenants or
agreements contained in this Agreement for purposes of determining satisfaction
of any condition contained herein or shall in any way limit Purchaser’s right to
seek indemnity under Article IX.
(b) Purchaser
shall notify each Seller and the Special Fiduciary and Trustee in writing of,
and shall contemporaneously provide such Seller and the Special Fiduciary and
Trustee with true and complete copies of any and all information or documents
relating to, and shall use all commercially reasonable efforts to cure before
the Closing, any event, transaction or circumstance, as soon as practicable
after it becomes known to Purchaser, occurring after the date of this Agreement
that causes or may cause any covenant or agreement of Purchaser under this
Agreement to be breached or that renders or may render untrue in any material
respect any representation or warranty of Purchaser contained in this Agreement
as if the same were made on or as of the date of such event, transaction or
circumstance. Purchaser shall notify such Seller and the Special
Fiduciary and Trustee in writing of, and shall use all commercially reasonable
efforts to cure, before the Closing, any violation or breach, as soon as
practicable after it becomes known to Purchaser, of any representation,
warranty, covenant or agreement made by Purchaser in this Agreement, whether
occurring or arising before, on or after the date of this
Agreement. No notice given pursuant to this
Section 6.07(b) shall have any effect on the representations,
warranties, covenants or agreements contained in this Agreement for purposes of
determining satisfaction of any condition contained herein or shall in any way
limit a Seller’s right to seek indemnity under any provision of this Agreement
or any of the Ancillary Agreements providing such Seller with such a
right.
47
Section
6.08 Fulfillment of
Conditions.
Each
party shall execute and deliver at the Closing each Ancillary Agreement that
such party is required hereby to execute and deliver as a condition to either
party’s obligations pursuant to Article VII, and, subject to the limitations
elsewhere set forth in this Agreement, shall take all commercially reasonable
steps necessary or desirable and proceed diligently and in good faith to satisfy
each other condition to the obligations of the other party contained in this
Agreement (including the mutual conditions set forth in Section 7.01), and shall
not take or fail to take any action that could reasonably be expected to result
in the nonfulfillment of any such condition. The obligations of the
Special Fiduciary and Trustee under this Section 6.08 shall apply only as to the
ESOP.
Section
6.09 Further Action; Consents;
Filings.
(a) Upon
the terms and subject to the conditions hereof, each of the parties hereto shall
use all requisite commercially reasonable best efforts to (i) take, or
cause to be taken, all appropriate action, and do, or cause to be done, all
things necessary, proper or advisable under applicable Law or otherwise to
consummate and make effective the transactions contemplated by this Agreement,
(ii) obtain from all applicable Governmental Entities all consents,
Licenses, permits, waivers, approvals, authorizations or orders required to be
obtained or made by Purchaser or each Seller in connection with the
authorization, execution and delivery of this Agreement and the consummation of
the transactions contemplated by this Agreement, and (iii) make all
necessary filings, and thereafter make any other required or appropriate
submissions, with respect to this Agreement and the transactions contemplated by
this Agreement required under any applicable Law.
(b) Each
Seller and the Special Fiduciary and Trustee shall give any notices to all third
parties, and use commercially reasonable best efforts to obtain any consents and
waivers from all third parties necessary (including such consents, novations and
amendments required under the Contracts listed in Section 3.28 of the
Disclosure Schedule) to consummate the transactions contemplated by this
Agreement.
Section
6.10 Public
Announcements.
Until the
earlier of the termination of this Agreement and the Closing Date, Purchaser, on
the one hand and the Sellers’ Representative and the Special Fiduciary and
Trustee on the other hand, shall consult with each other before issuing any
press release or otherwise making any public statements with respect to the
Agreement or the transactions contemplated by this Agreement. Until
the first anniversary of the date hereof, the Sellers’ Representative or any
other person acting on behalf of the Sellers or the Special Fiduciary and
Trustee will not issue any such press release or make any such public statement
that is not approved by the Purchaser, except as may be required by Law, in
which case the Sellers’ Representative or any other person acting on behalf of
the Sellers or the Special Fiduciary and Trustee shall make reasonable efforts
to consult with the Purchaser prior to the making of such public
statement.
48
Section
6.11 Assistance and
Cooperation.
(a) After
the Closing Date, Purchaser shall become primarily responsible for (a) filing
the Company’s audited financial statements for the year ended December 31, 2008
with the SEC; and (b) preparing and filing all Tax Returns of the Company due
after the Closing Date; provided, however, that
Purchaser, the Sellers and the Company shall (and shall cause their respective
Affiliates and Representatives to): (i) assist the other party in
assembling financial information for the year ended December 31, 2008 and
preparing any Tax Returns which such other party is responsible for preparing
and filing related to the Company; (ii) cooperate fully in preparing for any
audits of, or disputes with any Taxing Authority regarding, any Tax Returns of
the Company; (iii) make available to the other and to any Taxing Authority as
reasonably requested all information, records, and documents relating to
financial information for the year ended December 31, 2008 and Taxes of the
Company; (iv) provide timely notice to the other in writing of any pending or
threatened Tax audit or assessments of the Company for taxable periods for which
the other may have liability under this Agreement; and (v) furnish the other
with copies of all correspondence received from any Taxing Authority in
connection with any Tax audit with respect to any taxable period for which the
other may have liability under this Agreement. In the event of any
Tax audit with respect to the Company, the Sellers and the Company shall not
negotiate and settle with the applicable Taxing Authority without the written
consent of Purchaser.
(b) If,
as of the Closing Date, the audits of the Company’s financial statements as of
and for the years ended December 31, 2006 and 2007, have not been completed by
Xxxxx Xxxxxx PLLC, and Purchaser has waived the completion of the audits as a
condition to close the transactions contemplated by this Agreement, the Sellers
and the Company shall cooperate and provide Purchaser with assistance in
completing the audit that is reasonably requested, and which shall include the
Sellers making appropriate and commonly accepted written representations to
Xxxxx Xxxxxx PLLC to facilitate the completion of the audit.
Section
6.12 Employee Benefit
Plans.
The
Parties acknowledge and agree that the Purchaser may desire to terminate certain
of the Company Plans set forth on Section 3.16(b) of the
Disclosure Schedule. In the event Purchaser desires to
terminate any of such employee benefit plans (which indication shall be in
writing), the Company and the Sellers’ Representative hereby agree to effect
such termination.
49
Section
6.13 Sellers’
Representative.
The
Sellers, by their execution of this Agreement, hereby designate Xxxxxx Xxxxxxxx
as their representative (the “Sellers’
Representative”). In case of Xxxxxx Xxxxxxxx’x death or
disability, the Sellers shall designate an alternate Sellers’ Representative
within ten (10) days of such event. The Sellers shall be bound by any
and all actions taken by the Sellers’ Representative with respect to all matters
arising under this Agreement and the Escrow Agreement, as well as in resolving
all disputes or other issues between Purchaser and the Sellers arising hereunder
or thereunder at or following Closing. The Sellers authorize the
Sellers’ Representative to reimburse himself from distributions received by him
from the Escrow Fund for all costs, expenses and payments incurred by him in his
capacity as Sellers’ Representative. The Sellers’ Representative
shall be indemnified from and against any and all claims, demands, liabilities,
costs and expenses (including, without limitation, reasonable attorneys’ fees),
arising from or related to any acts undertaken (and any omissions to act) in his
capacity as Sellers’ Representative, except to the extent attributable to
Sellers’ Representative’s gross negligence or willful misconduct. The
Sellers, by their approval of the transactions contemplated in this Agreement,
agree to bear the costs of such expense reimbursement and indemnification on a
pro-rata basis in accordance with their pro-rata fully-diluted equity interest
in the Company immediately prior to the Closing. Purchaser shall be
entitled to rely upon any communication or writings given or executed by the
Sellers’ Representative. All notices to be sent to Sellers pursuant
to this Agreement may be addressed to the Sellers’ Representative, and any
notice so sent in accordance with Section 10.01 shall be deemed notice to all of
the Sellers.
Section
6.14 Approval of Schedule
1.
Each
Seller and the Special Fiduciary and Trustee hereby acknowledges and approves
the accuracy of Schedule
1.
Section
6.15 Cooperation of Purchaser
Relating to ESOP.
Following
the Closing, Purchaser will (a) reasonably cooperate with, in response to any
specific requests from, “NewCo” (as defined in Section 7.03(w)) and the
administrators and fiduciaries of the ESOP in connection with facilitating final
distributions from the ESOP, and (b) Purchaser’s 401(k) plan will accept
eligible rollover distribution in cash from the ESOP as to ESOP participants who
are employed by the Company provided Purchaser is not aware of any circumstances
that might cause the ESOP to fail to satisfy Code Section
401(a). Notwithstanding the foregoing, Purchaser shall not be
required to incur any out-of-pocket cost associated with such agreement,
Purchaser will not exercise any discretion with respect to the ESOP, and
Purchaser will not be a fiduciary as to the ESOP, an administrator, or have any
liability with respect to the ESOP as a result of such agreement.
Section
6.16 Reimbursement of Audit
Fees.
The
Purchaser will reimburse Sellers for the fees of Xxxxx Xxxxxx PLLC incurred in
connection with the audit of the financial statements previously reviewed by
Xxxxxx, Thresher & Xxxxxxxx P.C. which have been prepared as of and for the
years ended December 31, 2006 and 2007. Notwithstanding the
foregoing, the Sellers will be responsible for and hold Purchaser harmless from
and against any liability for Taxes related to the correction of any errors or
omissions discovered in such financial statements which are identified in
writing by Xxxxx Xxxxxx PLLC, as well as any fees and expenses of Xxxxx Xxxxxx
PLLC for any services requested by the Company in connection
therewith.
50
Section
6.17 Employee Confidentiality,
Invention Assignment, Non-Solicitation and Non-Competition
Agreement.
Sellers
shall use its best efforts to cause each of the Company’s Employees listed on
Schedule 6.17 to sign the Form of Employee Confidentiality, Invention
Assignment, Non-Solicitation and Non-Competition Agreement attached as Exhibit B, and shall
deliver the same at Closing to be effective as of the Closing Date.
CONDITIONS
TO CLOSING
Section
7.01 Conditions to the
Obligations of Each Party to Consummate the Transaction.
The
obligations of the parties hereto to consummate the purchase and sale of the
Company Shares and the other transactions which are to occur at the Closing
pursuant to Article
II are subject to the satisfaction or, if permitted by applicable Law,
waiver of the following conditions:
(a) No
Governmental Entity shall have issued any Order which is then in effect and has
the effect of making the transactions contemplated by this Agreement illegal or
otherwise prohibiting the consummation of the purchase and sale of the Company
Shares and the other transactions which occur at the Closing pursuant to Article
II.
(b) All
consents, approvals, authorizations and Licenses legally required to be obtained
to consummate the purchase and sale of the Company Shares and the other
transactions which occur at the Closing pursuant to Article II shall have
been obtained from all Governmental Entities.
(c) The
Escrow Agent shall have executed and delivered the Escrow Agreement, and such
agreement shall be in full force and effect.
Section
7.02 Additional Conditions to the
Obligations of Each Seller and the Special Fiduciary
and Trustee. The
obligation of each Seller and the Special Fiduciary and Trustee to consummate
the sale of the Company Shares to Purchaser and the other transactions which
occur at the Closing pursuant to Article II is subject
to the satisfaction or waiver of each of the following further conditions:
(a) Each
of the representations and warranties of Purchaser contained in this Agreement
shall be true, complete and correct in all material respects (other than
representations and warranties subject to “materiality” or “Material Adverse
Effect” limitations or exceptions, which shall be true, complete and correct in
all respects) both as of the date of this Agreement and as of the Closing Date
as if made as of the Closing Date (other than representations and warranties
which address matters only as of a certain date, which shall be true, complete
and correct as of such certain date), except where the failure of such
representations and warranties to be true and correct, would not, either
individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect on Purchaser’s ability to consummate the transactions
contemplated by this Agreement or to perform its obligations hereunder, and the
Sellers’ Representative and the Special Fiduciary and Trustee shall have
received a certificate of an officer of Purchaser, acting in his or her capacity
as such, to such effect.
51
(b) Purchaser
shall have performed or complied in all material respects with all covenants and
agreements required by this Agreement to be performed or complied with by it on
or prior to the Closing Date, and the Sellers’ Representative and the Special
Fiduciary and Trustee shall have received a certificate of an officer of
Purchaser, acting in such officer’s capacity as such, confirming such
performance and compliance.
(c) As
of the Closing Date, the Sellers’ Representative and the Special Fiduciary and
Trustee shall have received from Purchaser the following
documents: (i) a certificate of existence and good standing from the
Purchaser’s state of incorporation as to the corporate status of Purchaser, (ii)
a true and complete copy of the resolutions, certified by the Secretary of
Purchaser, adopted by the Board of Directors of Purchaser, authorizing the
execution, delivery and performance of this Agreement and the Ancillary
Agreements to which Purchaser is a party and all transactions contemplated by
this Agreement and thereby, (iii) a certificate from the Secretary of Purchaser
as to the incumbency and signatures of the officers who will execute documents
at the Closing or who have executed this Agreement, (iv) a certificate from the
Secretary of Purchaser that its Certificate of Incorporation has not been
amended since the date of the certificate described in Section 7.02(c)(ii), and
(v) such other documents and instruments, (if any), as the Sellers’
Representative may reasonably request in order to effectuate the transactions
contemplated by this Agreement.
(d) Purchaser
shall have executed and delivered the Escrow Agreement, and such agreement shall
be in full force and effect.
(e) All
corporate approvals of Purchaser required for the lawful consummation of the
transactions contemplated by this Agreement and the Ancillary Agreements to
which Purchaser is a party shall have been obtained and shall be in full force
and effect.
Section
7.03 Additional Conditions to the
Obligations of Purchaser.
The
obligation of Purchaser to consummate the purchase of the Company Shares from
each Seller and the Special Fiduciary and Trustee and the other transactions
which occur at the Closing pursuant to Article II is subject
to the satisfaction or waiver of each of the following further
conditions:
(a) Each
of the representations and warranties of each Seller contained in this Agreement
shall be true, complete and correct in all material respects (other than
representations and warranties subject to “materiality” or “Material Adverse
Effect” limitations or exceptions, which shall be true, complete and correct in
all respects) both as of the date of this Agreement and as of the Closing Date
as if made as of the Closing Date (other than representations and warranties
which address matters only as of a certain date, which shall be true, complete
and correct as of such certain date), except where the failure of such
representations and warranties to be true and correct, would not, either
individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect on the Business of the Company, and Purchaser shall have received
a certificate from each Seller to such effect.
52
(b) Each
Seller and the Special Fiduciary and Trustee shall have performed or complied in
all material respects with all covenants and agreements required by this
Agreement, to be performed or complied with by it, on or prior to the Closing
Date and Purchaser shall have received a certificate from each Seller and the
Special Fiduciary and Trustee, to such effect.
(c) Purchaser
shall have received the Certificates, duly endorsed (or accompanied by duly
executed stock powers).
(d) There
shall have been no Material Adverse Effect on the Business or on the Assets and
Properties or the Liabilities of the Company, and no event shall have occurred
which would reasonably be expected to result in a Material Adverse Effect on the
Business since January 1, 2008.
(e) All
consents and waivers of third parties and novations and amendments to Contracts
required in connection with the transactions contemplated by this Agreement
shall have been obtained.
(f) Intentionally
Omitted.
(g) Intentionally
Omitted.
(h) Xxxxxx
Xxxxxxxx shall have signed and delivered to Purchaser an employment agreement
(the “Xxxxxx
Xxxxxxxx Employment Agreement”) in
substantially the form of Exhibit C-1 hereto,
and the Xxxxxx Xxxxxxxx Employment Agreement shall be in full force and effect,
(ii) Xxxxxxx Xxxxx shall have signed and delivered to Purchaser an employment
agreement (the “Xxxxxxx
Xxxxx Employment
Agreement”) in substantially the form of Exhibit C-2 hereto,
and the Xxxxxxx Xxxxx Employment Agreement shall be in full force and effect,
and (iii) each of the individuals listed on Schedule 7.03(h)
shall have signed and delivered to Purchaser an employment agreement (the “Form Employment Agreement”)
in substantially the form of Exhibit C- 3
hereto, and the Form Employment Agreement in such form shall be in full force
and effect for each such person.
(i) Xxxxxx
Xxxxxxxx shall have signed and delivered to Purchaser a non-competition
agreement (the “Xxxxxx
Xxxxxxxx Non-Competition Agreement”)
in substantially the form of Exhibit D-1 hereto,
and the Xxxxxx Xxxxxxxx Non-Competition Agreement shall be in full force and
effect, (ii) Xxxxxxx Xxxxx shall have signed and delivered to Purchaser a
non-competition agreement (the “Xxxxxxx Xxxxx Non-Competition Agreement”)
in substantially the form of Exhibit D-2 hereto,
and the Xxxxxxx Xxxxx Non-Competition Agreement shall be in full force and
effect, (iii) Xxxxxxx Xxxxxxxx shall have signed and delivered to Purchaser a
non-competition agreement (the “Xxxxxxx Xxxxxxxx Non-Competition
Agreement”) in substantially the
form of Exhibit
D-3, hereto, and the Xxxxxxx Xxxxxxxx Non-Competition Agreement shall be
in full force and effect.
(j) Custom
Product Technologies, LLC shall have signed and
delivered to the Purchaser the Form of Sales Representative Agreement in
substantially the form of Exhibit
E.
53
(k) The
Company and Heritage Family Limited Partnership shall have entered into the Form
of Lease Agreement with respect to the facility located at 00 Xxxx Xxxxxx,
Xxxxxxxxx, Xxxxxxxxxxxxx, in substantially the form of Exhibit
F.
(l) Purchaser
shall have received resignations from each of the Company’s directors and
officers listed on Schedule
2.
(m) Each
customer of the Company from whom over One Hundred Thousand Dollars
($100,000) in revenues was received during fiscal year 2007, each of the
suppliers listed in Section 7.03(m)(i) of the
Disclosure Schedule and each of the sales representatives listed in Section 7.03(m)(ii) of the
Disclosure Schedule shall have continued to transact business with the
Company and otherwise to act substantially in accordance with the terms of its
Business Contract consistent with the established course of conduct or, to the
extent there is no Business Contract, its course of performance with the Company
over the last twelve (12) months. Each such customer, supplier or
sales representative shall not have sought, or indicated any intention to seek,
a reduction in the prices it currently pays for products and services of the
Company, an increase in the price it currently charges the Company for supplier
products and services or sales representatives services, as the case may be, or
any other material modification of any payment term or other material term
applicable to its purchases of products and services of the Company or sales to
the Company or sales to the Company’s customers, as applicable.
(n) Each
of Xxxxxx Xxxxxxxx, Xxxxxxx Xxxxx, and Xxxxxxx Xxxxxxxx shall have executed and
delivered the Escrow Agreement, and such agreement shall be in full force and
effect.
(o) A
copy of the financial statements previously reviewed by Xxxxxx, Thresher &
Xxxxxxxx P.C. which have been prepared as of and for the years ended December
31, 2006 and 2007 shall have been audited by Xxxxx Xxxxxx PLLC and any errors or
omissions identified as a result of such audit shall have been resolved to
Purchaser’s satisfaction.
(p) As
of the Closing Date, Purchaser shall have received from the Sellers’
Representative the following documents: (i) a certificate of
existence and good standing from the state of incorporation as to the corporate
status of the Company, (ii) a true and complete copy of the Certificate of
Incorporation of the Company and all amendments thereto certified by the
applicable state of incorporation, (iii) a true and complete copy of the Bylaws
of the Company certified by the Secretary thereof, and (iv) such other documents
and instruments (if any) as Purchaser may reasonably request in order to
effectuate the transactions contemplated by this Agreement and the Ancillary
Agreements.
(q) The
Company shall provide evidence that the Company has paid all Indebtedness and
satisfied all obligations owed to its creditors necessary to release all
Encumbrances, and otherwise permit the Purchaser to obtain clear title to the
Assets and Properties, or the Company shall have obtained payoff letters and
releases from such creditors, in form and substance reasonably satisfactory to
the Purchaser, which contain payoff and release information with respect to the
satisfaction of such obligations and the release of all such Encumbrances, and
provided such payoff letters to the Purchaser.
54
(r) Purchaser
shall have received evidence of the payment of the outstanding balance of the
mortgage receivable related to the Xxxx Xxxxxxxx Street facility.
(s) Intentionally
Omitted.
(t) Intentionally
Omitted.
(u) The
Special Fiduciary and Trustee shall continue to serve in its present capacity as
the sole trustee of the ESOP through the Closing Date with responsibility for
the transactions contemplated by the Agreement. The Special Fiduciary
and Trustee shall have determined, and provided to Purchaser, a written
instrument evidencing such determination, that (i) the consideration to be
received by the ESOP pursuant to the transactions contemplated hereby is fair to
the ESOP from a financial point of view, (ii) the consideration to be paid to
the ESOP for its Company Shares is not less than adequate consideration and
(iii) the consummation of the transactions contemplated hereby is fair and in
the interests of the ESOP participants and beneficiaries.
(v) Prior
to the Closing, the Special Fiduciary and Trustee shall have obtained on behalf
of the ESOP, a fairness opinion from an independent third party retained by the
Special Fiduciary and Trustee regarding the transactions contemplated
hereby. Such fairness opinion shall state that (i) the consideration
to be received by the ESOP pursuant to the transactions contemplated hereby is
fair to the ESOP from a financial point of view and (ii) such independent third
party shall have determined that the consideration to be paid to the ESOP for
its Company Shares is not less than adequate consideration.
(w) On
or before, but effective as of the Closing Date, the Company shall take all
actions necessary to cause (i) the Company to cease to be the plan sponsor of
the ESOP, (ii) the Company and its Affiliates to cease to be adopting employers
under the ESOP, (iii) The Retirement Company, Inc., an "S corporation"
(within the meaning of Code Section 1361) owned by one or more of the Sellers
and which is not a Subsidiary of the Company (“NewCo”) to become the sole plan
sponsor of the ESOP, which shall assume sole responsibility for the ESOP,
including without limitation, paying benefits thereunder, (iv) NewCo to retain a
professional third party administrator to administer the ESOP, and (v) NewCo to
convert the ESOP into a profit-sharing plan, terminate the plan and distribute
the accumulated account balances to plan participants after obtaining a
determination from the IRS that the ESOP is a qualified plan at
termination.
(x) At
or before the Closing, the Sellers shall deliver to the Purchaser a
certification of the Special Fiduciary and Trustee representing and warranting
that, as of the Closing Date, all of the representations and warranties by or on
behalf of the Special Fiduciary and Trustee contained in this Agreement are true
and correct in all respects.
(y) Prior
to the Closing, the Company shall deliver to the Purchaser satisfactory evidence
that Company Shares held by the ESOP are not pledged and are no longer subject
to an Encumbrance.
(z) Prior
to the Closing, Purchaser shall have received an opinion from counsel to the
Special Fiduciary and Trustee in form and substance reasonably acceptable to
Purchaser.
55
(aa) Each
officer and director of the Company and its Affiliates and Xxxxxx Xxxxxxxx and
Xxxxxxx Xxxxx as fiduciaries to the ESOP shall irrevocably waive any and all
right of indemnification that any such person may have against the Company, its
Affiliates, all other adopting employers under the ESOP, and their respective
affiliates, except to the extent insurance retained by the Company prior to the
Closing Date is available to cover such claims but for such waiver.
ARTICLE
VIII
TERMINATION,
AMENDMENT AND WAIVER
Section 8.01 Termination.
This
Agreement may be terminated and the transactions contemplated by this Agreement
may be abandoned at any time prior to the Closing Date, notwithstanding any
requisite adoption and approval of this Agreement, as follows:
(a) by
mutual written consent duly authorized by Sellers, the Special Fiduciary and
Trustee and Purchaser;
(b) by
either Purchaser, the Special Fiduciary and Trustee or Sellers if the Closing
shall not have occurred on or before December 31, 2008; provided, however, that the
right to terminate this Agreement under this Section 8.01(b) shall not be
available to any party whose action or failure to act has been the cause of or
resulted in the failure of the transactions contemplated by this Agreement to
occur on or before such date and such action or failure to act constitutes a
breach of this Agreement;
(c) by
either Purchaser, the Special Fiduciary and Trustee or Sellers, if any Order
preventing the consummation of the transactions contemplated by this Agreement
shall have been entered by any court of competent jurisdiction and shall have
become final and nonappealable;
(d) by
Purchaser, upon a breach in any material respect of any covenant or agreement on
the part of any Seller or the Special Fiduciary and Trustee set forth in this
Agreement, or if any representation or warranty of any Seller or the Special
Fiduciary and Trustee shall have become untrue or incorrect in any material
respect either as of the date of this Agreement or as of the Closing Date, in
either case such that the conditions set forth in Section 7.03 would not be
satisfied (a “Terminating
Seller Breach”);
(e) by
Sellers or the Special Fiduciary and Trustee upon a breach in any material
respect of any covenant or agreement on the part of Purchaser set forth in this
Agreement, or if any representation or warranty of Purchaser shall have become
untrue or incorrect in any material respect as of the date of this Agreement or
as of the Closing Date, in either case such that the conditions set forth in
Section 7.02 would not be satisfied (a “Terminating Purchaser Breach”); or
(f) the
right of any party hereto to terminate this Agreement pursuant to this
Section 8.01 will remain operative and in full force and effect regardless
of any investigation made by or on behalf of any party hereto, any Person
controlling any such party or any of their respective officers, directors or
Representatives, whether prior to or after the execution of this
Agreement.
56
Section
8.02 Effect of
Termination.
Except as
provided in Section 8.03, in the event of termination of this Agreement
pursuant to Section 8.01, this Agreement shall forthwith become void, there
shall be no liability under this Agreement on the part of any party hereto or
any of its Affiliates or any of its or their officers or directors, and all
rights and obligations of each party hereto shall cease; provided, however, that
nothing herein shall relieve any party hereto from liability for the willful or
intentional breach of any provisions of this Agreement prior to its termination;
and provided, further,
that the provisions of Section 6.03(b), this Section 8.02,
Section 8.03, Article IX and Article X shall remain in full force and
effect and survive any termination of this Agreement.
Section
8.03 Expenses; Liquidated
Damages.
All
Expenses incurred in connection with this Agreement and the transactions
contemplated by this Agreement shall be paid by the party incurring such
Expenses, whether or not the transactions contemplated by this Agreement are
consummated. Notwithstanding the foregoing, the Purchaser shall
promptly pay to Sellers an amount equal to Two Million Dollars ($2,000,000) in
cash in the event this Agreement is terminated by Sellers pursuant to Sections
8.01(b) or 8.01(e). The Sellers shall promptly pay Purchaser an
amount equal to Two Million Dollars ($2,000,000) in cash in the event this
Agreement is terminated by Purchaser pursuant to Sections 8.01(b) or
8.01(d).
ARTICLE
IX
SURVIVAL,
INDEMNIFICATION AND ESCROW
Section
9.01 Survival.
The
covenants, obligations, representations and warranties of Purchaser, Sellers,
the Special Fiduciary and Trustee, and the Company contained in this Agreement,
or in any document delivered pursuant to this Agreement, shall be deemed to be
material and to have been relied upon by the parties hereto notwithstanding any
investigation prior to the Closing and shall survive the date of Closing until
the termination of the Escrow Agreement; and shall not be merged into any
documents delivered in connection with the Closing; provided, however, that the
covenants, obligations, representations and warranties of Purchaser, Sellers,
the Special Fiduciary and Trustee, and the Company regarding (a) power and
authority to enter into this Agreement and the Ancillary Agreements (Sections
3.01, 3.02, 4.01, 4.02, 5.01, 5.02), (b) title to Assets and Properties, and
Company Shares (Section 3.05), (c) regulatory compliance (Section 3.09), (d)
Taxes (Section 3.15), (e) Intellectual Property (Section 3.13), (f)
capitalization and equity ownership (Section 3.17), and (g) equity ownership
(Section 4.08) shall survive the Closing Date indefinitely.
Section
9.02 Escrow
Fund. On or as
soon as reasonably practicable after the Closing Date, in accordance with
Section 2.04(b), the Escrow Amount shall be deposited with U.S. Bank, National
Association (or its successor in interest or other institution selected by
Purchaser with the consent of the other parties to the Escrow Agreement, which
consent shall not be unreasonably withheld), as escrow agent (the “Escrow
Agent”). The Escrow Amount so deposited, together with
interest and other income thereon, if any, shall constitute the “Escrow Fund” and shall be
governed by the terms set forth in this Agreement and in the Escrow
Agreement. The Escrow Fund shall be the sole source of funds
available to compensate Purchaser pursuant to the indemnification obligations of
the other parties hereto and any claims against the Special Fiduciary and
Trustee for any Losses resulting from any breach by the Special Fiduciary and
Trustee of any of its covenants, obligations, representations or warranties or
breach or untruth of any covenant, obligation, representation, warranty, fact or
conclusion contained in this Agreement, any Ancillary Agreement or any document
delivered pursuant to which it is a party, including any indemnification claim
made by Purchaser under this Article IX; provided, however, that
the limitations contained in this Section 9.02 shall not apply to recovery for
inaccuracy in or breach of a representation, warranty or obligation contained in
Sections 3.01, 3.02, 3.05(c), 3.15, 3.17, 4.01. 4.02 and the last sentence of
4.08 or a claim based on willful misconduct or fraud. The Escrow Agreement shall
have a term of two (2) years and shall provide for the release of one half (1/2)
of the Escrow Fund on the first anniversary thereof, net of the estimated
value of any asserted claims, which estimated value shall be withheld from the
amount released, and the remaining one half (1/2) on the second anniversary
thereof, also net of the estimated value of asserted claims, which estimated
value shall be withheld from the amount released.
57
Section
9.03 Indemnification.
(a) Indemnification by the
Sellers from the Escrow Fund. From and after the Closing Date,
subject to the limitations set forth in this Article IX and solely
from the Escrow Fund, the Sellers promptly shall indemnify, defend and hold
harmless (and upon demand shall reimburse) Purchaser and the directors,
officers, stockholders, employees, Affiliates and agents of Purchaser,
respectively (the “Indemnified
Parties”), against any and all claims, actions, demands, suits,
proceedings, assessments, judgments, losses, costs, and expenses (including
Legal Expenses) and other damages (individually and collectively a “Loss”) resulting from (i) any
breach by the Sellers or the Company of any of its covenants, obligations,
representations or warranties or breach or untruth of any covenant, obligation,
representation, warranty, fact or conclusion contained in this Agreement, any
Ancillary Agreement or any document delivered pursuant to which it is a party,
(ii) any action, claim or investigation relating to or arising out of the
ownership, licensing, operation, action, inaction or conduct of the Business, or
any of the Assets or Properties related to the Business, relating to periods of
time prior to Closing, (iii) any and all Taxes imposed on or against the Company
as a result of any failure to either (A) properly withhold any such Taxes on any
payments made by the Company to any Person prior to the Closing Date or (B)
report properly any such payments on a Tax Return, including the reporting of
such payments on an incorrect Tax Return, (iv) the maintenance, administration,
and operations of the ESOP, including but not limited to claims made against or
with respect to the ESOP or the tax qualification of the ESOP or any predecessor
or successor plan, whether before, on or after the Closing Date; (v) all
present, former, and future obligations and liabilities (including, without
limitation, contingent obligations and liabilities) of the Company, its
Affiliates, and the Indemnified Parties to, or with respect to, the ESOP; (vi)
fiduciary breaches or prohibited transactions relating to the ESOP; (vii)
litigation or other action brought by current or former ESOP participants or
fiduciaries, the United States Department of Labor or any other federal or state
governmental agency relating to the ESOP; (viii) any loss, liability,
assessment, taxes, interest, penalties, judgments, and employee benefit claims
(including any and all costs and fees related to proceedings establishing such
loss, liability, assessment, taxes, interest, penalties, judgments, or employee
benefit claims), with respect to (A) the ESOP, (B) each of the Company Plans
(other than the ESOP) to the extent arising out of events occurring or relating
to periods, on or before the Closing Date, including, without limitation, any
loss arising from the failure of the Needletech Products, Inc. Cafeteria Plan to
satisfy the requirements of Code Section 125 (including, without limitation
and solely for this purpose, any tax gross up payment the Company or the
Purchaser or either of their successors may voluntarily choose to make to the
Company's employees to put such employees in the same after-tax situation as if
such failure had not occurred), and (C) each employee benefit plan, as such term
is described in Section 3(3) of ERISA (including, but not limited to, any such
employee benefit plan that is not subject to some or all of the provisions of
ERISA), which was not sponsored, maintained, or contributed to by the Company or
any of its Affiliates, but which was sponsored, maintained, or contributed to by
any of the Company’s ERISA Affiliates, either presently or at any time, (ix) any
breach by the Special Fiduciary and Trustee (A) of any of its covenants,
obligations, representations or warranties or breach or untruth of any covenant,
obligation, representation, warranty, fact or conclusion contained in this
Agreement or any document delivered pursuant to which it is a party, or (B) in
its capacity as trustee of the ESOP, its negligence, breach of fiduciary duty,
violation of ERISA or breach of contract, and (x) the
Company’s indemnification of the Special Fiduciary and
Trustee. Any indemnification payment pursuant to the foregoing shall
include interest at a rate equal to eight percent (8%) (the “Rate”) from the date the
loss, costs, expenses or damages were incurred until the date of payment; provided, however, the Rate
shall not be payable with respect to attorneys’ fees incurred until such date as
the underlying claim is determined to be payable. Notwithstanding the
foregoing, (i) if all individual Losses do not exceed One Hundred Twenty Five
Thousand Dollars ($125,000) in the aggregate, they shall not be deemed to be
Losses for which indemnification is required under this Section 9.03(a) and (ii)
in no event shall the Sellers be responsible for any Losses in excess of, in the
aggregate, the amount of the Escrow Fund at any given time, and Purchaser shall
look solely to the Escrow Fund for reimbursement of Losses, the Sellers having
no additional personal liability therefor; provided, however, that once
the One Hundred Twenty Five Thousand Dollar ($125,000) threshold is exceeded,
Losses shall include the first dollar of Loss. The limitations
contained this 9.03(a) shall not apply to recovery for inaccuracy in or breach
of a representation, warranty or obligation contained in Sections 3.01, 3.02,
3.05(c), 3.15, 3.17, 4.01, 4.02 and the last sentence of 4.08 or a claim based
on willful misconduct or fraud.
58
(b) Intentionally
Omitted.
(c) Indemnification by
Purchaser.
(i) Purchaser
shall promptly indemnify, defend, and hold harmless (and upon demand shall
reimburse) the Sellers and the Special Fiduciary and Trustee against any Loss
resulting from (A) any breach by Purchaser of any of its covenants, obligations,
representations or warranties or breach or untruth of any covenant, obligation,
representation, warranty, fact or conclusion contained in this Agreement or any
certificate or document of Purchaser delivered pursuant to this Agreement, and
(B) any claim arising out of the conduct of the Business after Closing, except
for failure to obtain consents, if any, for the assignment of the Contracts and
except those directly or indirectly resulting solely from a breach by the
Company, the Sellers or the Special Fiduciary and Trustee of any
representations or covenants of this Agreement. Any indemnification
payment pursuant to the foregoing shall include interest at the Rate from the
date the loss, costs, expenses or damages were incurred until the date of
payment; provided,
however, the Rate shall not be payable with respect to attorneys’ fees
incurred until such date as the underlying claim is determined to be
payable.
59
(ii) Notwithstanding
anything in this Agreement to the contrary, and except for the liquidated
damages described in Section 8.03, the Company, each Seller and the Special
Fiduciary and Trustee agree that (i) to the extent the Company, any Seller, the
Special Fiduciary and Trustee or any of their respective Affiliates have
incurred any losses or damages in connection with this Agreement, (A) the
maximum aggregate liability of Purchaser and its respective Representatives and
Affiliates for such losses or damages, if liable therefor, will be limited to an
amount equal to Five Hundred Thousand Dollars ($500,000) in the aggregate,
except liability for fraud or intentional misconduct, to which such limit shall
not apply, and (B) in no event will the Company, any Seller, the Special
Fiduciary and Trustee or any of their respective Affiliates seek to recover any
money damages in excess of such amount from Purchaser, or its respective
Representatives and Affiliates in connection therewith.
Section
9.04 Procedure for
Indemnification.
(a) Notice. Within
thirty (30) days (or, if sooner, at least five (5) Business Days before an
answer or response is due) after receipt of written or actual notice of any
action or claim (the “Claim”) as to which it
asserts a right to indemnification, the party seeking indemnification hereunder
(the “Indemnitee”)
shall give written notice thereof (the “Notice”) to the Person from
whom indemnification is sought (the “Indemnitor”), provided that
the failure of the Indemnitee to give the Indemnitor notice within the specified
number of days shall not relieve the Indemnitor of any of its obligations
hereunder, but may create a cause of action for breach for damages directly
attributable to such delay. Indemnitor shall be liable to Indemnitee
with respect to Losses only so long as Indemnitee gives Indemnitor written
notice thereof prior to the expiration of the survival periods set forth in
Section 9.01.
(b) Third Party
Claims.
(i) If
any claim for indemnification by Indemnitee arises out of a Claim by a Person
other than Indemnitee, the Indemnitor shall be entitled to assume the defense
thereof, by written notice to the Indemnitee within fifteen (15) days after
receipt of the Notice. Indemnitor shall thereupon take all steps or
commence proceedings to defeat or compromise any such Claim, including retaining
counsel reasonably satisfactory to the Indemnitee. Except as
otherwise provided herein, all costs, fees and expenses with respect to any such
Claim shall be borne by Indemnitor. If the Indemnitor assumes the
defense of a Claim, it shall not settle such Claim unless such settlement
includes as an unconditional term thereof a release by the claimant of the
Indemnitee, reasonably satisfactory to the Indemnitee except that Indemnitor
shall not, without the prior written consent of Indemnitee, directly or
indirectly require Indemnitee to take or refrain from taking any action, or make
any public statement, or consent to any settlement, which it reasonably
considers to be against its interest. Indemnitee shall have the right
to participate at its own expense, in such proceedings, but control of such
proceedings shall remain exclusively with Indemnitor.
60
(ii) If
the Indemnitor shall fail to notify the Indemnitee of its desire to assume the
defense of any such claim or action within the prescribed period of time, then
the Indemnitee may assume such defense in such manner as it may deem
appropriate, and the Indemnitor shall be bound by any determination made or any
settlement thereof effected by the Indemnitee. The Indemnitor shall
be permitted, at its own expense, to join in such defense and to employ its own
counsel but control of such proceedings shall remain exclusively with
Indemnitee.
(iii) Indemnitor
and Indemnitee agree to make available to each other, their counsel and other
representatives, all information and documents reasonably available to them
reasonably requested by the other which relate to any such claim or action, and
to render to each other such reasonable assistance as may be reasonably
requested in order to insure the proper and adequate defense of such claim or
action, but any costs or expenses related thereto shall be borne by Indemnitor;
provided
that any failure (after written notice with specificity and an
opportunity to cure) shall not relieve the Indemnitor of any of its obligations
hereunder but may create a cause of action for breach for damages directly
attributable to such failure.
(c) Other
Claims. In the event of any Claim other than those provided
for in subsection (b) hereof, Indemnitee shall be entitled to indemnification as
provided herein.
(d) Payment of
Claims. Amounts payable by the Indemnitor to the Indemnitee
under this Section 9.04 shall be payable by the Indemnitor (or the Escrow Agent
under the Escrow Agreement) as incurred by the Indemnitee. In the
event Indemnitor (or the Escrow Agent under the Escrow Agreement) fails to pay,
timely and fully, any such amounts, Indemnitee may pay such Claim. In
such event, the Indemnitee may recover from the Indemnitor, in addition to the
amount so paid, (i) interest on the amount claimed at the Rate, and (ii)
reasonable attorneys’ fees in connection with the enforcement of payment under
this Section 9.04; provided,
however, that in the event the Escrow Agent fails to pay any amounts, the
Sellers shall not be liable for any of the foregoing interest or fees or for
reimbursing Purchaser if it pays such Claim.
(e) No
Set-Off. The Indemnitee’s right to indemnification under this
Section 9.04 shall not be subject to set-off for any claim by the Indemnitor
against the Indemnitee.
Section
9.05 Assignment by
Purchaser. No
consent by any party hereto shall be required for any assignment or reassignment
of the rights of Purchaser under this Article
IX.
61
ARTICLE
X
GENERAL
PROVISIONS
Section
10.01 Notices.
All
notices, requests, claims, demands and other communications hereunder shall be
in writing and shall be given (and shall be deemed to have been duly given upon
confirmation of delivery) by delivery in person, by telecopy or facsimile, by
registered or certified mail (postage prepaid, return receipt requested) or by a
nationally recognized courier service to the respective parties at the following
addresses (or at such other address for a party as shall be specified in a
notice given in accordance with this Section 10.01):
(a)
|
if
to the Sellers generally, c/o the Sellers’
Representative:
|
|
Xxxxxx
Xxxxxxxx
|
||
NeedleTech
Products, Inc.
|
||
00
Xxxx Xxxxxx
|
||
Xxxxxxxxx,
Xxxxxxxxxxxxx 00000
|
||
with
a copy to:
|
||
Xxxxxx
X. Xxxxxx, Attorney at Law
|
||
000
Xxxxx Xxxx Xxxxxx
|
||
Xxxxxxxxx,
XX 00000
|
||
Attention: Xxxxxx
X. Xxxxxx
|
||
Fax: (000)
000-0000
|
||
(b)
|
if
to Purchaser:
|
|
Theragenics
Corporation
|
||
0000
Xxxxxxx Xxxxxxxxxx Xxx
|
||
Xxxxxx,
Xxxxxxx 00000
|
||
Attention:
Xxxxx Xxxxx
|
||
Fax: (000)
000-0000
|
||
with
a copy to:
|
||
Xxxxxx
Xxxxxxxxx LLP
|
||
Fourteenth
Floor
|
||
0000
X. Xxxxxxxxx Xxxxxx, X.X.
|
||
Xxxxxxx,
Xxxxxxx 00000-0000
|
||
Attention: Xxxx
Xxxxxx
|
||
Fax: (000)
000-0000
|
||
(c)
|
if
to any individual Seller for a matter
|
|
not
germane to any other Seller,
|
||
to
such Seller at the address set forth below
|
||
such
Seller’s name on Schedule
1.
|
62
(d)
|
if
to the Special Fiduciary and Trustee:
|
|
Rockland
Trust Company
|
||
0000
Xxxxxxxxxx Xxxxxx
|
||
Xxxxxxx,
Xxxxxxxxxxxxx 00000
|
||
Attention:
Xxxxx X. Xxxxx
|
||
Fax: (000)
000-0000
|
||
with
a copy to:
|
||
Xxxxx
& Xxxxxxxx LLP
|
||
000
Xxxxxx Xxxxxx
|
||
Xxxxxx,
Xxxxxxxxxxxxx 00000
|
||
Attention: Xxxxxx
X. Xxxxxxx
|
||
Fax: (000)
000-0000
|
Section
10.02 Rights and Remedies
Cumulative. The
rights and remedies provided in this Agreement are cumulative and are not
exclusive of any rights or remedies that either party may otherwise have at Law
or in equity.
Section
10.03 Severability.
If any
term or other provision of this Agreement is invalid, illegal or incapable of
being enforced by any rule of Law or public policy, all other conditions and
provisions of this Agreement shall nevertheless remain in full force and effect
so long as the economic or legal substance of the transactions contemplated by
this Agreement is not affected in any manner materially adverse to any
party. Upon such determination that any term or other provision is
invalid, illegal or incapable of being enforced, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original
intent of the parties as closely as possible in a mutually acceptable manner to
the fullest extent permitted by applicable Law in order that the transactions
contemplated by this Agreement may be consummated as originally contemplated to
the fullest extent possible.
Section
10.04 Assignment; Binding Effect;
No Third Party
Beneficiary. Except as
provided in Section 9.05, neither this Agreement nor any of the rights,
interests or obligations hereunder shall be assigned by any of the parties
hereto (whether by operation of Law or otherwise) without the prior written
consent of the other parties hereto. This Agreement shall be binding
upon and shall inure to the benefit of the parties hereto and their respective
successors and permitted assigns. Notwithstanding anything contained
in this Agreement to the contrary, other than Article IX, nothing
in this Agreement, expressed or implied, is intended or shall be construed to
confer on any person other than the parties hereto or their respective
successors and permitted assigns any rights or remedies under or by reason of
this Agreement.
Section
10.05 Governing Law.
This
Agreement shall be governed by, and shall be construed and enforced in
accordance with, the internal Laws of the State of Georgia applicable to
contracts made and to be performed entirely within that state, and no effect
shall be given to any conflict-of-laws principles thereof directing the
application of any Law other than the laws of the State of
Georgia. Except as otherwise expressly set forth in this Agreement or
the Ancillary Agreements, the United States District Court for the Northern
District of Georgia and the state courts of the State of Georgia situated within
the County of Xxxxxx in the State of Georgia shall have exclusive jurisdiction
over all disputes between the parties hereto arising out of or relating to this
Agreement and the agreements, instruments and documents contemplated by this
Agreement. The parties hereby consent to and agree to submit to the
exclusive jurisdiction of such courts. Each of the parties hereto
waives, and agrees not to assert in any such dispute, to the fullest extent
permitted by applicable Law, any claim that (i) such party is not personally
subject to the jurisdiction of such courts, (ii) such party and such party’s
property is immune from any legal process issued by such courts, or (iii) any
litigation commenced in such courts is brought in an inconvenient
forum.
63
Section
10.06 Waiver of Jury
Trial. Each
party hereto hereby irrevocably waives all right to trial by jury in any
proceeding (whether based on contract, tort or otherwise) arising out of or
relating to this Agreement or any transaction or agreement contemplated by this
Agreement or the actions of any party hereto in the negotiation, administration,
performance or enforcement hereof.
Section
10.07 Headings;
Interpretation. The
descriptive headings contained in this Agreement are included for convenience of
reference only and shall not affect in any way the meaning or interpretation of
this Agreement. The parties have participated jointly in the
negotiation and drafting of this Agreement. In the event an ambiguity
or question of intent or interpretation arises, this Agreement shall be
construed as if drafted jointly by the parties, and no presumption or burden of
proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement.
Section
10.08 Counterparts.
This
Agreement may be executed and delivered (including by facsimile or e-mail
transmission) in one or more counterparts, and by the different parties hereto
in separate counterparts, each of which when executed and delivered shall be
deemed to be an original but all of which taken together shall constitute one
and the same agreement.
Section
10.09 Mediation.
In the
event of any dispute or claim arising out of or relating to the interpretation
of this Agreement, or breach hereof (a “Dispute”), each of the
parties hereto subject to the Dispute shall in good faith first negotiate a
written resolution of the Dispute within a period not to exceed thirty (30) days
from the date of written notice of the Dispute. The negotiations
shall be conducted by representatives of the subject parties who have
authorization to resolve the Dispute. In the event that the subject
parties cannot negotiate a written resolution to the Dispute during this thirty
(30)-day negotiation period, and still prior to filing any claims in a court of
law, the subject parties shall then submit the Dispute to non-binding
mediation. The mediation may be initiated by the written request of
any party subject to the Dispute, and shall commence within fifteen (15) days of
the receipt of such notice and shall be conducted in Atlanta, Georgia, in
accordance with the mediation procedures established by the mediator, unless
otherwise agreed to by the subject parties. The subject parties will
attempt to each agree upon the selection of a mediator. The mediation
shall not exceed a period of thirty (30) days. Each of the subject
parties shall bear his or her own expenses in connection with such mediation,
and the fees and expenses of the mediator shall be shared equally between the
subject parties. In the event that the subject parties do not resolve
the Dispute as a result of such mediation or in the event that the Dispute is
not resolved within sixty (60) days of the commencement of the Dispute, any
party subject to the Dispute may seek to resolve the Dispute in a court of
competent jurisdiction or seek other legal or equitable resolution in compliance
with Sections 10.05 and 10.06. Notwithstanding the foregoing, any
party hereto may at any time apply to any court of competent jurisdiction for
injunctive relief in the event of an alleged breach of this Agreement or
otherwise to prevent irreparable harm, provided that party complies with
Sections 10.05 and 10.06.
64
Section
10.10 Entire
Agreement.
This
Agreement (including the Schedules and Exhibits hereto), together with the
Ancillary Agreements and the Confidentiality Agreement constitute the entire
agreement among the parties with respect to the subject matter hereof and
supersede all prior agreements and understandings among the parties with respect
thereto. No addition or modification of any provision of this
Agreement shall be binding upon any party hereto unless made in writing and
signed by all parties hereto.
[Remainder
of Page Intentionally Left Blank]
65
IN WITNESS WHEREOF, the
parties hereto have caused this Agreement to be executed as of the date first
written above by their respective officers thereunto duly
authorized.
PURCHASER:
THERAGENICS
CORPORATION
By: /s/ M. Xxxxxxxxx
Xxxxxx
M. Xxxxxxxxx Xxxxxx
Chief Executive Officer
|
|
SELLERS’
REPRESENTATIVE:
By: /s/ Xxxxxx
Xxxxxxxx
Xxxxxx Xxxxxxxx
|
|
THE COMPANY
(for purposes of the
representations
and warranties contained in
Article III, VI, VII,
IX):
NEEDLETECH
PRODUCTS, INC.
By: /s/ Xxxxxx
Xxxxxxxx
Name: Xxxxxx
Xxxxxxxx
Title: President
|
|
SPECIAL FIDUCIARY AND
TRUSTEE,
on behalf of the
NeedleTech Products Employee
Stock Ownership Plan
and the trust established
thereunder:
ROCKLAND
TRUST COMPANY
By: /s/ Xxxxxxx X.
Xxxxx
Xxxxxxx X. Xxxxx
Title: Senior Vice President
|
SELLERS:
/s/ Xxxxxx
Xxxxxxxx
Xxxxxx
Xxxxxxxx
/s/ Xxxxxxx
Xxxxx
Xxxxxxx
Xxxxx
/s/ Xxxxxxx
Xxxxxxxx
Xxxxxxx
Xxxxxxxx
|
`